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Abstract 
 
Chronic rhinosinusitis (CRS) is a chronic inflammatory disease that has multifactorial origins 
including bacterial colonisation and biofilms, anatomical abnormalities and immune activation. It is 
characterised by persistent inflammation of the sinonasal mucosa that may cause pain, nasal 
discharge, nasal blockage and headaches. Current treatments for CRS include saline lavages, 
intranasal and oral corticosteroid therapy and surgery; though despite this, a number of refractory 
cases prove difficult to cure. The need for novel therapeutics for CRS that address the underlying 
inflammatory disease process without toxicity is required. 
 
Similar to most chronic inflammatory states, CRS demonstrates activation of a number of central 
inflammatory pathways including, but not exclusive to; nuclear-factor kappa-B (NF-κB) and up 
regulation of inflammatory cytokines TNF-α and IL-1β. These pathways may serve as novel 
therapeutic drug targets for many inflammatory conditions. 
 
Drug discovery focusing on inflammatory pathway modulators may use synthetic or natural 
sources. When natural extracts are sourced, such as in this manuscript, then it becomes 
necessary to develop methods that allow high-throughput screening and purification of compounds 
based on their favourable biological properties. Bioactivity-guided investigation and purification of 
minimally fractionated (crude) biological extracts is the focus of this manuscript using extracts that 
are known active modulators of IL-1β and NF-κB pathways in vitro. 
 
This manuscript screened fractions of crude extracts using a well-established in vitro model of 
inflammation – human monocyte leukaemia cell line (THP-1) differentiated to macrophages by 
phorbol-12-myristate-13-acetate (PMA). Cytokine modulation in this system is quantified using 
human IL-1β and TNF-α AlphaScreen enzyme-linked immunosorbent assay (ELISA). 
Subsequently modulation of the NF-κB pathway is quantified by use of a high-content imaging 
assay targeting NF-κB translocation to the nucleus. Purification of active constituents of these 
extracts requires fractionation; three generations of fractions were required to reach a near-pure 
compound from the original extract. 
 
Four crude extracts selected for their modulation of IL-1β and NF-κB were fractionated based on 
solubility in common organic solvents and screened with the most active fraction (named 44E) 
selected as it inhibited all pathways tested (TNF-α, IL-1β and NF-κB). 44E was then re-fractionated 
using liquid chromatography revealing 22 sub fractions of which one showed continual inhibition of 
these pathways (F2). F2 was then further fractionated using high performance liquid 
chromatography yielding 29 fractions in which a number showed modulation of these pathways. All 
experiments were performed using weight/volume-related dilutions of the dried fractions at 1 x 10-
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4%, 1 x 10-6%, 1 x 10-8% and 1 x 10-10%. Final generation fractions that modulated these pathways 
are named H2, H6, H8, H9, H11, H12, H18 and H22. These possible therapeutically active extracts 
were assessed for toxicity to the system using a cell-viability assay. H2 H6 and H22 do not affect 
the cell viability. 
 
Near-pure biological extracts H2, H6 and H22 significantly inhibit the inflammatory pathways IL-1β 
and TNF-α while inhibiting NF-κB translocation. These extracts show promise in serving as 
potential anti-inflammatory therapeutic agents to treat chronic inflammatory diseases such as CRS. 
 iv 
Declaration by author 
 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my 
thesis is the result of work I have carried out since the commencement of my research higher 
degree candidature and does not include a substantial part of work that has been submitted to 
qualify for the award of any other degree or diploma in any university or other tertiary institution. I 
have clearly stated which parts of my thesis, if any, have been submitted to qualify for another 
award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the policy and procedures of The University of Queensland, the thesis be made available 
for research and study in accordance with the Copyright Act 1968 unless a period of embargo has 
been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
 
 v 
Publications during candidature 
 
Alternative and emerging therapies for chronic rhinosinusitis – A systematic review 
ENT Clinics (Journal) – accepted for publication May 2016 
Griffin, A; Cabot, P; Wallwork, B; Panizza, Ben 
  
Publications included in this thesis 
 
No publications included 
 
 vi 
Contributions by others to the thesis  
 
Significant contributions were made to the research design, data analysis and thesis structure and 
editing by Associate Professor Peter Cabot, my primary supervisor. Significant contributions 
toward overall research plan and guidance by Associate Professors Ben Wallwork and Ben 
Panizza, my clinical supervisors on this project. 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
 
None 
 
 vii 
Acknowledgements 
 
To my trusted supervisors Associate Professor Peter Cabot, Associate Professor Ben Wallwork 
and Associate Professor Ben Panizza; I thank you for the opportunity to undertake this project and 
the support and guidance you have shown me. This experience has challenged me and through it I 
know I have become a better scientist and clinician.  I look forward to working with you all in the 
future. 
 
To my help at ‘ground zero’ on the laboratory floor I extend many thanks to Sarah Faz and Nga 
Phan without whom I’d surely be still chasing my tail. 
 
To the Princess Alexandra Research Foundation for their research grant I cannot thank you 
enough. Full time research is only possible with kind and unencumbered grants like their clinical 
research fellowship. 
 
To my partner, Bronnie. If I could award you with an honoury MPhil I would. You listened to me talk 
endlessly of lab failures and frustrations and gave up many weekends and weeknights together so 
I might complete my thesis. Thank you. 
  
 viii 
Keywords 
Chronic rhinosinusitis, drug discovery, inflammation, activity guided fractionation, chromatography, 
NF-κB, IL-1β, TNF-α 
 
Australian and New Zealand standard research classifications (ANZSRC) 
 
ANZSRC code: 111502, Pharmacology and pharmaceutical sciences 60% 
ANZSRC code: 030401, Biologically active molecules, 20% 
ANZSRC code: 030402, Biomolecular modelling and design, 20% 
 
Fields of research (FoR) classification 
 
FoR code: 1115, Pharmaceutical sciences, 100% 
 
 
 
 
  
 ix 
Table of Contents 
 
Abstract……………………………………………………………………………………………………….i 
Declaration by author……………………………………………………………………………………..iv 
Publications during thesis………………………………………………………………………………..v 
Publications included in thesis………………………………………………………………………….v 
Contributions by others…………………………………………………………………………………..vi 
Statements of parts of the thesis submitted to qualify for the award of another degree…….vi 
Acknowledgments………………………………………………………………………………………...vii 
Keywords…………………………………………………………………………………………………..viii 
Australian and New Zealand standard research classifications………………………………...viii 
Fields of research classification………………………………………………………………………viii 
 
List of Figures & Tables…………………………………………………………………………………...1 
List of Abbreviations used in the thesis………………………………………………………………10 
 
 
Chapter 1 – Introduction 
1.1 Definitions and Epidemiology of Chronic Rhinosinusitis…………………………………………...13 
1.2 Inflammation in Chronic Rhinosinusitis………………………………………………………………13 
1.2.1 Inflammatory Cells and Tissue Remodelling……………………………………………..13 
1.2.2 Inflammatory Cytokines in Chronic Rhinosinusitis………………………………………14 
1.3 Inflammatory Pathways Implicated in Chronic Rhinosinusitis……………………………………..15 
1.3.1 IL-1β Inflammatory pathway………………………………………………………………..15 
1.3.1.1 Production of IL-1β……………………………………………………………….15 
1.3.1.2 Secretion of IL-1β…………………………………………………………...……15 
1.3.1.3 IL-1β receptor signalling…………………………………………………………16 
1.3.1.4 IL-1β transcriptional targets……………………………………………………..18 
1.3.2 TNF-α Inflammatory pathway………………………………………………………………18 
 x 
1.3.2.1 Production and secretion of TNF-α…………………………………………….18 
1.3.2.3 TNF-α receptor signalling………………………………………………………..18 
1.3.2.4 TNF-α transcriptional targets……………………………………………………19 
1.3.3 NF-κB Pathway………………….…………………………………………………………..19 
1.3.3.1 Canonical pathway……………………………………………………………….20 
1.3.3.2 Non-canonical pathway………………………………………………………….20 
1.3.4 Interactions between pathways……………………………………………………………21 
1.4 Treatments for Chronic Rhinosinusitis……………………………………………………………….22 
1.4.1 Topical agents ………………………………………………………………………………22 
1.4.2 Systemic agents…………………………………………………………………………….22 
1.4.3 Surgical management………………………………………………………………………23 
1.5 Drug discovery in chronic rhinosinusitis……………………………………………………………..24 
1.5.1 Rationale……………………………………………………………………………………..24 
1.5.2 Biological extracts as potential therapeutic targets for chronic rhinosinusitis………...24 
 1.5.2.1 Identifying desirable features in biological extracts…………………………..24 
1.5.2.2 Selecting extracts to screen…………………………………………………….25 
1.5.2.3 Ecobiotics™ biological extracts…………………………………………………25 
1.5.3 Selecting in vitro models for screening extracts in chronic rhinosinusitis……………..25 
1.5.3.1 THP-1 cells as an in vitro model for chronic rhinosinusitis…………………..26 
1.5.4 Methods of screening biological compounds…………………………………………….27 
1.5.4.1 Cytokine expression as a marker of inflammation……………………………27 
1.5.4.2 High throughput screening using signal transduction pathways…………….28 
1.5.5 Biological activity-guided fractionation for isolation of compounds…………………….30 
1.5.5.1 Crude extraction and solubility fractions……………………………………….30 
1.5.5.2 Silica gel column liquid chromatography fractionation……………………….31 
1.5.5.3 High-performance liquid chromatography fractionation……………………...33 
1.6 Summary………………………………………………………………………………………………..35 
1.7 Hypothesis and aims………………………………………………………………………………......37 
1.7.1 Hypothesis…………………………………………………………………………………...37 
 xi 
1.7.2 Aims…………………………………………………………………………………………..37 
 
 
Chapter 2 - Activity guided investigation of Ecobiotics™ bioactive extracts using 
immunofluorescence to quantify cytokines IL-1β and TNF-α modulation in LPS-stimulated, 
PMA-differentiated human monocytes 
2.1 Foreword………………………………………………………………………………………………..38 
2.2 Introduction……………………………………………………………………………………………..38 
2.2.1 Quantification of cytokines in biological systems………………………………………..39 
2.3 Materials and Methods………………………………………………………………………………..39 
2.3.1 Culturing THP-1 cells and differentiation…………………………………………………39 
2.3.2 Preparation of samples…………………………………………………………………….40 
2.3.3 Treating differentiated THP-1 cells………………………………………………………..40 
2.3.4 AlphaScreenELISA………………………………………………………………………….41 
2.3.5 Data analysis………………………………………………………………………………...41 
2.4 Results…………………………………………………………………………………………………..41 
2.4.1 First generation fractions of biological extracts modulate expression of pro-
inflammatory cytokines IL-1β and TNF-α in PMA-differentiated THP-1 cells……………….41 
2.4.2 Second generation fractions of biological extracts modulate expression of pro-
inflammatory cytokines IL-1β and TNF-α in PMA-differentiated THP-1 cells ………………58 
2.4.3 Third generation fractions of biological extracts modulate expression of pro-
inflammatory cytokines IL-1β and TNF-α in PMA-differentiated THP-1 cells……………...105 
2.5 Discussion……………………………………………………………………………………………..165 
2.6 Conclusions……………………………………………………………………………………………167 
 
 
 xii 
Chapter 3 – Activity-guided investigation of Ecobiotics™ bioactive extracts using 
immunofluorescence to quantify NF-κB translocation in LPS-stimulated, PMA-differentiated 
human monocytes 
3.1 Foreword………………………………………………………………………………………………168 
3.2 Introduction……………………………………………………………………………………………168 
3.3 Materials and Methods……………………………………………………………………………….169 
3.3.1 Culturing THP-1 cells and differentiation………………………………………………..169 
3.3.2 Preparation of samples……………………………………………………………………169 
3.3.3 Treating differentiated THP-1 cells………………………………………………………770 
3.3.4 Fluorescent immunohistochemistry……………………………………………………...170 
3.3.5 Quantitative fluorescent imaging analysis………………………………………………171 
3.3.6 Data analysis……………………………………………………………………………….171 
3.4 Results…………………………………………………………………………………………………171 
3.4.1 First generation fractions of biological extracts inhibit NF-ĸB translocation in PMA-
differentiated THP-1 cells……………...…………………………………………………….….171 
3.4.2 Second-generation fractions of 44E modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells………………………………………………………………………179 
3.4.3 Third generation fractions of biological extracts modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells………………………………………………………………………202 
3.5 Discussion…………………………………………………………………………………………….233 
3.5.1 First generation fractions of biological extracts modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells………………………………………………………………………234 
3.5.2 Second-generation fractions of 44E modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells………………………………………………………………………234 
3.5.3 Third generation fractions of biological extracts modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells………………………………………………………………………235 
3.6 Conclusions…………………………………………………………………………………………..236 
 
 
 xiii 
Chapter 4 – Effect of fractionated biological extracts on cell viability in PMA-differentiated 
THP-1 Cells 
4.1 Foreword………………………………………………………………………………………………237 
4.2 Introduction……………………………………………………………………………………………237 
4.3 Materials and Methods……………………………………………………………………………….238 
4.3.1 Culturing THP-1 cells and differentiation………………………………………………..238 
4.3.2 Preparing samples…………………………………………………………………………238 
4.3.3 Treating differentiated THP-1 cells………………………………………………………238 
4.3.4 MTT tetrazolium reduction assay………………………………………………………...238 
4.3.5 Absorbance…………………………………………………………………………………239 
4.3.6 Data analysis……………………………………………………………………………….239 
4.4 Results…………………………………………………………………………………………………239 
4.4.1 Cell viability assay of third generation fractions of biological extracts……………….239 
4.5 Discussion……………………………………………………………………………………………..247 
 
 
Chapter 5 - Discussion and Conclusions…………………………………………………………...250 
5.1 Summary………………………………………………………………………………………………254 
5.2 Future directions …………………………………………………………………………………..…254 
 
 
6.0 References……………………………………………………………………………………………257 
 
7.0 Appendices…………………………………………………………………………………………..267 
7.1 Appendix 1 - Alphabetical List of Materials………………………………………………………...267 
7.2 Appendix 2 – Standard curves………………………………………………………………………269 
7.2.1 Human IL-1β AlphaScreen ELISA Standard Curve……………………………………269 
7.2.2 Human TNF-α AlphaScreen ELISA Standard Curve…………………………………..270 
 1 
List of Figures & Tables 
 
Figure Name Page 
1.1 Pro-inflammatory cytokine release in response to extracellular 
stimulation by cytokines or lipopolysaccharide 
16 
1.2 IL-1β receptor signalling 17 
1.3 TNF-α receptor signalling 19 
1.4 NF-κB translocation pathway 21 
1.5 Schematic depicting an AlphaScreenELISA 28 
1.6 A schematic of the immunostaining of NF-κB for a quantitative 
immunoflorescent microscopy used in high-throughput screening 
29 
1.7 Overview of extraction and first fractionation of Ecobiotics™ extracts 31 
1.8 Overview of second fractionation via silica gel liquid chromatography 32 
1.9 Overview of third fractionation via reverse-phase high performance 
liquid chromatography 
 
34 
1.10 A diagram illustrating the flow scheme for the bioactivity-guided 
fractionation of Ecobiotics™ extracts 
36 
2.1 Nomenclature and crude-extract origins of first generation fractions 42 
2.2 44W modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
43 
2.3 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
45 
2.4 45W modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
47 
2.5 45E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
49 
2.6 46W modulates cytokine IL-1β and TNF-α expression in PMA- 51 
 2 
differentiated THP-1 cells 
2.7 46E stimulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
53 
2.8 47W stimulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
55 
2.9 47E stimulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
57 
2.10 Nomenclature of fractions of active first-generation fraction 44E 59 
2.11 F1 fraction of 44E stimulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
60 
2.12 F2 fraction of 44E inhibits cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
62 
2.13 F3 fraction of 44E modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
64 
2.14 F4 fraction of 44E inhibits cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
66 
2.15 F5 fraction of 44E modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
68 
2.16 F6 fraction of 44E modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
70 
2.17 F7 fraction of 44E modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
72 
2.18 F8 fraction of 44E modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
74 
2.19 F9 fraction of 44E modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
76 
2.20 F10 fraction of 44E inhibits cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
78 
 3 
2.21 F11 fraction of 44E does not modulate cytokine IL-1β and TNF-α 
expression in PMA-differentiated THP-1 cells 
80 
2.22 F12 fraction of 44E modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
82 
2.23 F13 fraction of 44E modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
84 
2.24 F14 fraction of 44E does not modulate cytokine IL-1β and TNF-α 
expression in PMA-differentiated THP-1 cells 
86 
2.25 F15 fraction of 44E modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
88 
2.26 F16 fraction of 44E does not modulate cytokine IL-1β and TNF-α 
expression in PMA-differentiated THP-1 cells 
90 
2.27 F17 fraction of 44E inhibits cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
92 
2.28 F18 fraction of 44E modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
94 
2.29 F19 fraction of 44E modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
96 
2.30 F20 fraction of 44E modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
98 
2.31 F21 fraction of 44E modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
100 
2.32 F22 fraction of 44E modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
102 
2.33 Load fraction of 44E modulates cytokine IL-1β and TNF-α expression 
in PMA-differentiated THP-1 cells 
104 
2.34 H1 fraction of F2 does not modulate cytokine IL-1β and TNF-α 
expression in PMA-differentiated THP-1 cells 
106 
 4 
2.35 H2 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
108 
2.36 H3 fraction of F2 stimulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
110 
2.37 H4 fraction of F2 stimulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
112 
2.38 H5 fraction of F2 stimulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
114 
2.39 H6 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
116 
2.40 H7 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
118 
2.41 H8 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
 
120 
2.42 H9 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
122 
2.43 H10 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
124 
2.44 H11 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
126 
2.45 H12 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
128 
2.46 H13 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
130 
2.47 H14 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
132 
2.48 H15 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 134 
 5 
PMA-differentiated THP-1 cells 
2.49 H16 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
136 
2.50 H17 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
138 
2.51 H18 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
140 
2.52 H19 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
142 
2.53 H20 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
144 
2.54 H21 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
146 
2.55 H22 fraction of F2 inhibits cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
148 
2.56 H23 fraction of F2 does not modulate cytokine IL-1β and TNF-α 
expression in PMA-differentiated THP-1 cells 
150 
2.57 H24 fraction of F2 does not modulate cytokine IL-1β and TNF-α 
expression in PMA-differentiated THP-1 cells 
152 
2.58 H25 fraction of F2 does not modulate cytokine IL-1β and TNF-α 
expression in PMA-differentiated THP-1 cells 
154 
2.59 H26 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
156 
2.60 H27 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
158 
2.61 H28 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
160 
2.62 H29 fraction of F2 modulates cytokine IL-1β and TNF-α expression in 162 
 6 
PMA-differentiated THP-1 cells 
2.63 Load fraction of F2 inhibits cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
 
164 
2.64 Summary of results for the release of inflammatory cytokines TNF-α 
and IL-1β in the three generations of fractions 
167 
3.1 Water and ethyl acetate-soluble fractions of extract 44 modulate NF-
ĸB translocation in PMA-differentiated THP-1 cells 
172 
3.2 Water and ethyl acetate-soluble fractions of extract 45 modulate NF-
ĸB translocation in PMA-differentiated THP-1 cells 
173 
3.3 Water and ethyl acetate-soluble fractions of extract 46 modulate NF-
ĸB translocation in PMA-differentiated THP-1 cells 
175 
3.4 Water and ethyl acetate-soluble fractions of extract 47 modulate NF-
ĸB translocation in PMA-differentiated THP-1 cells 
 
177 
3.5 F1 and F2 fractions of 44E modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
 
179 
3.6 F3 and F4 fractions of 44E modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
 
181 
3.7 F5 and F6 fractions of 44E do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
 
183 
3.8 F7 and F8 fractions of 44E do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
185 
3.9 F9 and F10 fractions of 44E modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
187 
 7 
3.10 F11 and F12 fractions of 44E inhibit NF-ĸB translocation in PMA-
differentiated THP-1 cells 
 
189 
3.11 F13 and F14 fractions of 44E do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
191 
3.12 F15 and F16 fractions of 44E do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
193 
3.13 F17 and F18 fractions of 44E stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
195 
3.14 F19 and F20 fractions of 44E stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
197 
3.15 F21 and F22 fractions of 44E stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
199 
3.16 Load fraction of 44E inhibits NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
 
201 
3.17 H1 and H2 fractions of F2 inhibit NF-ĸB translocation in PMA-
differentiated THP-1 cells 
203 
3.18 H3 and H4 fractions of F2 inhibit NF-ĸB translocation in PMA-
differentiated THP-1 cells 
205 
3.19 H5 and H6 fractions of F2 inhibit NF-ĸB translocation in PMA-
differentiated THP-1 cells 
207 
3.20 H7 and H8 fractions of F2 modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
209 
3.21 H9 and H10 fractions of F2 do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
211 
3.22 H11 and H12 fractions of F2 inhibit NF-ĸB translocation in PMA-
differentiated THP-1 cells 
213 
 8 
3.23 H13 and H14 fractions of F2 do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
215 
3.24 H15 and H16 fractions of F2 do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
217 
3.25 H17 and H18 fractions of F2 modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
219 
3.26 H19 and H20 fractions of F2 stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
221 
3.27 H21 and H22 fractions of F2 stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
223 
3.28 H23 and H24 fractions of F2 modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
225 
3.29 H25 and H26 fractions of F2 do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
227 
3.30 H27 and H28 fractions of F2 do not modulate NF-ĸB translocation in 
PMA-differentiated THP-1 cells 
229 
3.31 H29 and load fractions of F2 modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
232 
 
3.32 Summary of results for the translocation of NF-κB in three generations 
of fractions. 
 
236 
4.1 H2 does not affect cell viability in differentiated THP-1 cells 240 
4.2 H6 does not affect cell viability in differentiated THP-1 cells 241 
4.3 H8 affects cell viability in differentiated THP-1 cells 242 
4.4 H9 affects cell viability in differentiated THP-1 cells 243 
4.5 H11 affects cell viability in differentiated THP-1 cells 244 
4.6 H12 affects cell viability in differentiated THP-1 cells 245 
4.7 H18 affects cell viability in differentiated THP-1 cells 246 
 9 
4.8 H22 affects cell viability in differentiated THP-1 cells 247 
4.9 Summary of results for the third generation fractions undergoing the 
MTT cell viability assay. 
249 
 
  
 10 
List of Abbreviations used in the thesis 
 
CRS Chronic rhinosinusitis 
NF-κB Nuclear factor kappa-light-chain-
enhancer of activated B cells 
TNF-α Tumour necrosis factor-alpha 
IL-1β Interluekin-1 beta 
ELISA Enzyme-linked immunosorbent assay 
CRSwNP Chronic rhinosinusitis with nasal polyps 
CRSsNP Chronic rhinosinusitis without nasal 
polyps 
CT Computer tomographic 
Th1 T-helper cell -1 
Th2 T-helper cell -2 
IL-5 Interleukin-5 
IL-4 Interleukin-4 
IL-8 Interleukin-8 
INFλ Interferon gamma 
TGFβ Transforming growth factor beta 
IL-1RI & IL-1RII IL-1β receptor 1 & 2 
ILRAcP IL-1β receptor accessory protein 
IRAK IL-1 receptor associated kinases 
TRAF Tumour necrosis factor receptor 
associated factor 
MAPK Mitogen-activated protein kinase 
TACE TNF-α converting enzyme 
TNF-R1 & TNF-R2 TNF-α receptor 1 & 2 
SODD Silencer of death domain 
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Chapter 1 
Literature Review 
 
 
1.1 Definitions and Epidemiology of Chronic Rhinosinusitis 
Chronic rhinosinusitis (CRS) is a collective term used to describe two separate conditions; chronic 
rhinosinusitis with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). Most clinical 
guidelines state that CRS is defined by 8-12 weeks of chronic sinus inflammation consisting of 2 or 
more symptoms of nasal obstruction, blockage, congestion, discharge (anterior or posterior), facial 
pain, loss of smell and either endoscopic or computer tomographic imaging (CT) evidence of 
disease. These two subtypes are diagnostically separated by the presence of nasal polyps on 
visual inspection of the paranasal sinuses and sinonasal tract and with CT findings consistent with 
polyposis. Clinically it is thought that CRSsNP patients are more likely to complain of facial pain 
and rhinorrhoea while CRSwNP patients suffer more from nasal obstruction and loss of smell 
(hyponosmia).1 
 
CRS is a disease of significant health burden with 5-17% of the population affected. Overall burden 
of this disease is recognised as costs of healthcare for patient 
(medications/consultations/surgeries), cost to the healthcare system and overall economic costs 
secondary to absenteeism and reduced productivity. In the United States the total costs of the 
economic burden were estimated at $8.6 billion United States Dollars in 2007 although this amount 
does not include self-purchased prescriptions by the patient. Another estimation for expenditure is 
$1539 per patient, per year for the United States making it a significant health burden.2 
 
So far the only recognised risk factor for CRS is smoking3 however a 2012 European 
epidemiological study published an increased rate of late-onset asthma amongst CRS sufferers. 
Whether or not this strong link indicates causation is still debateable though the two diseases do 
co-exist regularly4.  
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1.2 Inflammation in Chronic Rhinosinusitis 
1.2.1 Inflammatory Cells and Tissue Remodelling 
The pathophysiology of CRS encompasses a multifactorial causation including bacterial 
infections/colonisations, bacterial biofilms, anatomical factors, bacterial superantigens, fungi and 
mucocillary dysfunction.5 Despite the ongoing scientific debate as to the importance of each of 
these factors6 the undeniable result is a persistent inflammatory state that is largely unresponsive 
to many antimicrobial therapies7. In CRSwNP, compared to CRSsNP, the pathophysiology is 
though to involve staphylococcal enterotoxins as a predominant inflammatory stimulus when 
compared to fungal colonisation.6  
 
Persistent inflammation requires inflammatory cell activation as well as increased inflammatory 
cytokines resulting in tissue remodelling and migration. This is characterised by predominantly T-
cell (T-helper cell-1 (Th1) and T-helper cell-2 (Th2)) and eosinophil-mediated inflammation8,9. The 
two subtypes of CRS differ in remodelling. CRSsNP is characterised by thickening of the basement 
membrane and fibrosis as well as goblet cell hyperplasia and mononuclear cell infiltration. 
CRSwNP is characterised by oedematous stroma with formation of psudocysts10.    
 
Eosinophils are associated in higher numbers with increased severity of CRS even post surgical 
management11. Eosinophil migration is mediated predominantly through Interleukin-5 (IL-5) 
chemotaxis12 and is self-propagated by autocrine activated degranulation in response to granule 
eotaxins released from eosinophils 13. Eosinophils also release proinflammatory cytokines14 and 
function as antigen presenting cells15 and hence stimulate a Th2 or mixed Th1/Th2 response2.  
 
The role of macrophages in chronic rhinosinusitis is established in both human and murine models 
of CRS with increased numbers with analysis using electron microscopy16 and histological 
staining17,18. Indeed, lower airways disease is strongly regulated by the alveolar macrophage. A 
2014 study by Banks et al was able to demonstrate significant increased macrophage cell markers 
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in CRSwNP independent of atopy and a trend of raised macrophage numbers across all ranges of 
CRS indicating that their likely role in the development and propagation of the persistent 
inflammatory state in CRS19. 
 
1.2.2 Inflammatory Cytokines in Chronic Rhinosinusitis 
Initial indications of the cytokine expression of CRSwNP tissue indicate of overrepresentation of IL-
4, IL-5, IL1, IL-8 and decreased levels of Interferon gamma (INFλ) and transforming growth factor 
beta (TGFβ)20. CRSsNP is thought to involve increased expression of IL-1, IL-3, IL-6, TNF-α21, 
IL22 and IL17A22. Although these two disease subtypes are often separated the reality is often a 
combination of the two at the level of the cytokine and cell signalling level certainly in the initial 
phases of mucosal injury where the major cytokine signalling occurs via IL-1β, TNF-β, IL-6 and IL-
8 to recruit macrophages, T-cells, eosinophils and neutrophils23. 
 
1.3 Inflammatory Pathways Implicated in Chronic Rhinosinusitis 
1.3.1 IL-1β Inflammatory pathway 
IL-1β is perhaps one of the most important cytokines in inflammation due to its potency as a pro-
inflammatory innate immune system mediator. It can cause activation of lymphocytes, increases in 
acute phase protein synthesis, and infiltration of lymphocytes in areas of infection24. 
 
1.3.1.1 Production of IL-1β 
Macrophages are responsible for the production of IL-1β from a precursor molecule (proIL-1β)25 
which has to undergo cleaving by capsase-1 enzyme to become active26. In order for mature IL-1β 
to be produced large protein complexes called inflammasones which are triggered by infections, 
stress and reactive oxygen species along with cell disruption24 
 
1.3.1.2 Secretion of IL-1β 
Secretion of IL-1β by mature activate immune cells is controlled by way of two pathways; the first is 
phosphorylase-dependant exocytosis which involved the loading of proIL-1β and capsase-1 into a 
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vesicle to be excreted and the second by secretion of small vesicles from the plasma membrane24. 
(See figure 1.1). 
 
Figure 1.1 – Pro-inflammatory cytokine release in response to extracellular stimulation by 
cytokines or lipopolysaccharide. 
Inhibitor of kappa-B kinase (IKK) complex is the target of activation from trans membrane receptors 
in response to lipopolysaccharide (LPS) and pro-inflammatory cytokines TNF-α, IL-1β and receptor 
activator of NF-κB ligand (RANKL). Once activated it allows degradation of the inhibitor of kappa-B 
complex and then translocation of the p50/RelA heterodimer to the nucleus to stimulate 
transcription and translation of pro-inflammatory cytokines IL01β, TNF-α and IL-6. 
 
1.3.1.3 IL-1β receptor signalling 
Although two receptors exist for IL-1β (Receptor IL-1RI and IL-1RII) only IL-RI is involved in signal 
transduction as it recruits a co-receptor (IL-1β receptor accessory protein or ILRAcP) and activates 
the Toll-IL-1 domains on the cytosolic domains of the receptor-co-receptor heterodimer24. First 
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cytosolic protein involved is a myeloid differentiation marker (MyD88) which binds to the 
heterodimer and allows recruitment of one of four IL-1 receptor associated kinases (IRAK) of which 
IRAK3 is the only inhibitor of signal transduction24,27 while IRAK4 is most commonly involved in 
signal transduction. This complex of IL-1R1, ILRAcP, MyD88 and IRAK4 forms a signalling 
molecule which results in the phosphorylation of IRAK4 then binding IRAK1 and IRAK2 before 
activating tumour necrosis factor (TNF)-receptor-associated factor 6 (TRAF6). TRAF6 then 
activates gene transcription via NF-κB and mitogen-activated protein kinases (MAPK) pathways28. 
(See figure 1.2). 
 
Figure 1.2 – IL-1β receptor signalling 
Free-IL-1β binds to the IL-1R1 attracting the IL-1RAcP to form a complex which allows binding of 
the MyD88 cytosolic protein. This protein then binds IRAK4 which in turn binds IRAK1/2 before 
binding TRAF6. TRAF6 then activates downstream signal transduction pathways NF-κB and p38 
MAPK. 
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1.3.1.4 IL-1β transcriptional targets 
Cytosolic signalling from IL-1β takes place via the NF-κB, p38 MAPK and c-Jun N-terminal kinase 
(JNK) pathways. JNK and c-Jun up regulate expression of genes encoding predominantly IL-6 and 
IL-8 while p38 MAPK stabilises the messenger RNA in the cytosol29. 
 
1.3.2 TNF-α Inflammatory pathway 
Central to both inflammatory conditions and neoplastic conditions, TNF-α is a monocyte and 
lymphocyte-derived cytokine that is thought to be pro-inflammatory and among the first cytokines 
released during an insult to a system30. Not all production of TNF-α may be pathological however 
with some levels associated with physiological functions of circadian rhythm of body temperature, 
sleep and appetite31. 
 
1.3.2.1 Production and secretion of TNF-α 
TNF-α is primary produced as a transmembrane protein arranged in stable homotrimers32. TNF-α 
converting enzyme (TACE), a metalloprotease, cleaves the membrane-bound protein releasing a 
soluble homotrimeric cytokine32.  
 
1.3.2.3 TNF-α receptor signalling 
Two receptors for TNF-α exist; TNF-α receptor 1 (TNF-R1) and TNF-α receptor 2 (TNF-R2). These 
receptors can bind both the membrane-bound form of TNF-α as well as the soluble32. Of the two 
receptors only one is found exclusively on immune cells (TNF-R2) and has a higher affinity for the 
membrane-bound TNF-α while TNF-R1 is more widely involved in TNF-α signalling33. 
TNF-α ligand binds the TNF-R1 at which point the silencer of death domain (SODD) dissociates 
from the receptor and the death domain-containing adaptor protein (TRADD) is recruited to the 
death domain of the TNF-R1 receptor. This TNF-R1/TRADD complex then binds the TNF receptor 
associated factor (TRAF) 2 and the receptor-interacting kinase (RIP). This allows requitement of 
the secondary signalling factors to activate the JNK/p 38 MAPK and the NF-κB pathways33. (See 
figure 1.3). 
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Figure 1.3 – TNF-α receptor signalling 
Free TNF-α binds to the TNFR1 trans membrane receptor causing the SODD to disassociate from 
the death domain and the TRADD can then bind. TRADD binding allows TRAF2 to bind along with 
RIP which then stimulates downstream signal transduction pathways. 
 
1.3.2.4 TNF-α transcriptional targets 
Through its two major downstream pathways NF-κB and p38 MAPK, TNF-α increases the 
translation of TNF-α, IL-β, IL-6, and matrix metalloproteinase-1 (MMP-1)34. TNF-α also stimulates 
transcription of Inhibitor of κB alpha (I-κBα), cyclooxygenase-2 (COX-2) and IL-6 via the NF-κB 
pathway35 
 
1.3.3 NF-κB Pathway 
NF-κB is a cell signalling and transcription factor that plays a central role in the maintenance, 
modulation and down regulation of cellular inflammatory response. The NF-κB protein is in fact 
made up of two proteins RelA and p50 and exists in its inactive form as a free floating cytosolic 
heterodimer bound to its inhibitor protein Inhibitor of κB (IκB)36. The I-kB family of proteins (I-kBα, I-
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kBβ and I-kBε) inhibit translocation of NF-κB to the nucleus by binding the nuclear localisation 
sequence (NLS). Activation of this pathway occurs through at least two pathways termed canonical 
and non-canonical36. 
 
1.3.3.1 Canonical pathway 
Shared by both the canonical and non-canonical pathway is the initial step in NF-κB activation 
which involves activation of I-κB kinase (IKK), an enzyme consisting of 3 proteins; IKKα, IKKβ and 
NF-κB essential modulator or NEMO. This enzyme induces phosphorylation and degradation of the 
I-κB inhibitor protein36 in response to activation by proximity to a surface receptor complex such as 
TRAF. Once free of its inhibitor protein the NF-κB heterodimer translocates to the nucleus and acts 
as a transcription factor to up regulate genes for IL-10, IL-6, COX-2, IL-8, IL1-β and INFλ37. (See 
figure 1.4) 
 
1.3.3.2 Non-canonical pathway 
This pathway of NF-κB activation responds to lymphotoxin-α (otherwise known as TNF-β) or 
receptor activator of NF-κB ligand (RANKL) to activate NF-κB inducible kinase (NIK) which in turn 
processes the precursor protein p100 into p52. A dimerization occurs between p52 and RelB which 
can then translocate to the nucleus and begin transcribing genes specific to this pathway38. (See 
figure 1.4). 
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Figure 1.4 – NF-κB translocation pathway 
Canonical activations begins with activation of a transmembrane receptor by binding of a TNF-
α/RANKL/IL-1β ligand. This activation activates the IKK which in turn signals the I-κB protein to 
degrade leaving the p50/RelA heterodimer to translocate to the nucleus. The non-canonical 
pathway begins with ligand activatin by lymphotoxin-α or RANKL activating NIK which in turn 
signals the phosphorylation of IKKα and the breakdown of p100 to p52 bound to RelB. This 
p52/RelB heterodimer then translocates to the nucleus. 
 
1.3.4 Interactions between pathways 
The three inflammatory pathways described are intimately linked both directly and indirectly. NF-κB 
is of course activated by TNF-α via its receptor-associated protein (TRAF)33. While IL-1β activates 
NF-κB also through the canonical pathway via TRAF639. Both TNF-α and NF-κB activation can 
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stimulate IL-1β up regulation31. Activation of NF-κB also inhibits and self-regulates inflammation by 
transcribing its own inhibitor I-κB36. 
 
1.4 Treatments for Chronic Rhinosinusitis 
1.4.1 Topical agents 
Saline lavage has been a mainstay of treating acute and chronic rhinosinusitis due to its 
availability, low cost and efficacy. Isotonic saline lavage in chronic rhinosinusitis is believed to 
reduce inflammatory markers such as leukotriene C4 in nasal mucosa for up to 4 hours following 
use 40. Subsequently they may play a role in reducing the motility of sinonasal pathogens such as 
Pseudomonas aeruginosa41. Saline lavages have good evidence to support their use in CRSsNP 
however data is inconclusive in their use for CRSwNP2,4. There is, however, a recommendation by 
the European Position Paper on CRS from 2012 that suggests they should be given to all CRS 
subtypes4. 
 
Inhaled or intranasal corticosteroids (INCS) have strong evidence for their use in all CRS subtypes 
2. INCS when used in CRSwNP has been shown to reduce cytokines IL-5 and decrease eotaxin 
expression as well as reduce eosinophil infiltration and TH2 concentration in nasal tissue42. 
 
Topical antifungals such as amphiterocin added to nasal lavage solutions has little evidence 
supporting its efficacy 43 and as such is not included in recent European guidelines 4. Topical 
(aerosolised or nebulised) antibiotics have some evidence for use in post-surgical patients only 
and no randomised trials have been reported in the literature2,44 
 
Intranasal decongestants, allergen desensitisation and antihistamines may be beneficial and are 
recommended as adjuncts for treating associated conditions or to aid management only2,4. 
 
1.4.2 Systemic agents 
Systemic corticosteroids, either orally absorbed or intravenous have strong evidence for their 
efficacy in acute rhinosinusitis 4 however their side effect profile limits their long-term use in chronic 
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conditions such as CRS. Their use in CRSsNP is not routinely recommended or supported by the 
literature. In CRSwNP, however, their use has strong evidence2,4. When given to 15 patients in a 
trial by Lennard et al in 2000 they were found to reduce the levels of IL-6 and TNF-α in the nasal 
mucosa of CRS suffers 45 suggesting a possible mechanism by which corticosteroids induce their 
clinical effect. 
 
Systemic antibiotic therapy using broad-spectrum antibiotics of the macrolide class for a prolonged 
period (12 weeks) has been shown to reduce symptoms of CRS46. Patients treated with long tem 
macrolides have shown significantly reduced nasal Il-8 and IL-5 and granulocyte colony stimulating 
factor (G-CSM) in the nasal lavage fluid 47 indicating a possible mechanism through the NFkB 
pathway47-49. Other classes of antibiotic classes such as tetracyclines and trimethoprim-
sulfamethoxazole have not been shown to have the same efficacy in reducing symptoms of CRS48. 
 
There is evidence for treating CRSwNP with biological drugs omalizumab, an anti-immunoglobbin-
E (anti-IgE) antibody, reslizumab and mepalizumab, which are anti IL-5 antibodies. Omalizumab, 
which is used in refractory asthma, has been shown in a few modest randomised controlled trials 
to reduce symptoms and features of CRSwNP however its use cannot be extrapolated to 
CRSsNP50 or patients without severe asthma51. Anti-IL-5 antibodies have been shown to 
significantly reduce the symptoms of CRSwNP in patients with an elevated mucous IgE level52 in 
twon randomised-controlled trials53 and are recommended for use in severe asthma patients with 
CRSwNP2. 
 
1.4.3 Surgical management 
Surgical management of CRS is indicated when maximal medical therapy fails4. The obstructed 
osteomeatal complex is now recognised as being the major precursor for CRSsNP although the 
surgical opening and ventilating of the sinuses is not usually enough alone to halt this 
inflammation4,54. 
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1.5 Drug discovery in chronic rhinosinusitis 
1.5.1 Rationale 
Drug discovery is a billion dollar industry with novel drugs requiring an estimated 1.7 billion US 
dollars to go from idea to the pharmacy shelf55. Coupled with this is the estimated decline in 
productivity of research in this area with an estimated 1 in 13 discoveries making it to market in 
2003 compared to 1 in 8 during the years 1995 and 200055. These factors illustrate the need for 
cheaper, high-throughput screening in the discovery of novel therapeutics. 
 
Drug discovery is the discovery of new chemical entities; either synthetic or naturally occurring. 
Naturally occurring drugs may be plant based, animal or microbiological, the former is more 
commonly seen in later phase clinical drug trials56.  
 
1.5.2 Biological extracts as potential therapeutic targets for chronic rhinosinusitis 
Naturally occurring compounds such as procyanidins57, polyphenolic extracts (olive oil)58, fruit 
extracts59 and lunasin (soybean) are known to inhibit the NF-κB pathway and hence reduce 
production of pro-inflammatory cytokines. Naturally occurring compounds and especially edible 
compounds are compelling to study as novel anti-inflammatory targets as their non-toxicity in 
humans is already well established.  
 
It is important to mention that there are negative effects to finding a naturally occurring novel drug 
and these primarily relate to the impact on the species itself (especially if the molecule cannot be 
synthesised) and on a more economic scale the intellectual property of naturally occurring 
compounds is often much debated and can cause a slowing of discovery due to withdrawal of 
commercial funding sources56. 
 
1.5.2.1 Identifying desirable features in biological extracts 
Koehn and Carter have listed common molecular features of naturally occurring compounds and 
compare these to the traditional drug paradigm. They found these naturally occurring compounds 
are more likely to be; greater numbers of chiral centres, increased steric complexity, higher 
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numbers of oxygen molecules and greater molecular rigidity to name a few60. Traditionally drug 
discovery followed simple rules such as Lipinski’s Rule of 5’s whereby molecules were thought to 
be more bioavailable if they had less than 5 hydrogen bonds, less than 10 hydrogen bond 
acceptors, molecular weight of less than 500 Daltons and a partition coefficient log P of less than 
556. Naturally occurring molecules do not, however, follow this basic paradigm and no such criteria 
exists for these targets. 
 
1.5.2.2 Selecting extracts to screen 
There exists a multitude of ways to select extracts to screen for drug discovery ranging from 
random selection to highly specified. Random selection is a viable method of drug discovery when 
vast databases of natural products are available for high-throughput screening around a specific 
bioassay56. Ethnopharmacology relates to the study around indigenous drugs while the traditional 
approach uses ancient medicine practices to guide drug discovery. Finally Zoo-pharmacogsony 
involves the study of animal behaviour (towards plants) to guide drug discovery56. Ecobiotics has a 
library of extracts from indigenous Australian plants collected using zoo-pharmacogsony that have 
been selected for suspected inflammatory pathway modulatory activity. The exact methods used 
by Ecobiotics to choose botanicals with suspected inflammatory modulatory activity is subject to 
confidentiality and unknown to the author. 
 
1.5.2.3 Ecobiotics™ biological extracts 
Ecobiotics is a small biotechnology company, which studies native Australian environments to 
guide the selection of possible bioactive extracts. They have kindly donated their extracts for the 
purpose of this research. The extracts provided are of single plant origin and are not combination 
extracts.  
 
1.5.3 Selecting in vitro models for screening extracts in chronic rhinosinusitis 
Once the specific targets are identified (in this case pro-inflammatory mediators) and extracts have 
been selected (Ecobiotics™) the next step is to select and refine the bioassay(s) that will be used 
to identify these properties. As outlined in section 1.2.1, CRS is a disease entity that combines 
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multiple subtypes including many combinations of inflammatory cells. No one model is likely to be 
completely representative of this; though a model with crossover between the subtypes, that is 
human and immortal is likely to be the most appropriate for the purposes of screening extracts for 
these properties. 
 
1.5.3.1 THP-1 cells as an in vitro model for chronic rhinosinusitis 
THP-1 cells are a human monocyte leukaemia cell line isolated from a human subject. THP-1 cells 
can be differentiated from monocyte to a macrophage-like cell with the addition of Phorbol-12-
myristate-13-acetate (PMA) or 1,25-dihydroxyvitamin D3 (VD3)61. Ex vivo macrophages are difficult 
to study for high-throughput screening due to their relative inability to culture not to mention their 
harvest requires sometimes extremely invasive procedures such as bronchoscopy61. The 
remaining issue using immortal cell lines such as THP-1’s lies in the differentiation to macrophage-
like cell by PMA or VD3. A study by Daigneault et al studied the differentiation of THP-1 cells by 
PMA in various treatment protocols and compared this to isolated human monocyte-derived 
macrophages and monocytes. Their overall conclusion was that THP-1 cells when treated with 
PMA closely relate to the monocyte-derived human macrophage in surface receptors, morphology 
and activity of cytokines TNF-α and IL-1β. Interestingly the PMA-differentiated THP-1 cells 
continued to polarize toward a type 1 macrophage (M1) while the human monocyte-derived 
macrophage was more similar to a type 2 macrophage (M2). The ability to modulate these 
phenotypes did exist, however, for both cells61. 
 
Using PMA-differentiated human monocytes (THP-1 cells) as an immortal cell line for high-
throughput screening has significant advantages. It allows for study of human macrophages on a 
large, repeatable scale. Their use in screening biological extracts has been well established in the 
literature 62,63. In CRS specifically the macrophage plays a cell-signalling role in both sub-types of 
the disease making it an acceptable screening cell for this disease process. Using an in vitro model 
of nasal epithelial cells could present a greater opportunity for greater phenotypic retention than 
immortal cell lines though differences in inflammatory phenotypes taken from different disease 
subtypes (CRSwNP donors verses CRSsNP donors) though this could introduce variability in 
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results64. Further to this extrapolation to other diseases of the results would be more difficult if such 
a selective model of inflammation was used. 
 
Eosinophil cell models were investigated for use in this screening process as eosinophils are the 
predominant inflammatory cell present in CRS however the eosinophil cell lines EoL-1 and HL-60 
clone 15 cells65 are both problematic; EoL-1 cells do not have a receptor for IL-5, a cytokine central 
to eosinophil-mediated inflammation66 and they differentiate in the presence of pro-inflammatory 
cytokine INF-λ and TNF-α into cells closely resembling monocyte-derived macrophages67. HL-60 
clone 15 cells do respond to IL-568 however they differentiate to resemble a neutrophil-like cell in 
the presence of dimethylsulfoxide (DMSO), the solvent used in our extracts69. It was for these 
above reasons an eosinophil model was not trialled in our screening bioassays. When investigation 
the usefulness of IL-5 as a therapeutic target for this project was undertaken it was thought that 
this might skew the focus toward CRSwN-specific inflammatory pathways as IL-5 concentrations in 
CRSsNP are significantly lower.70  
 
1.5.4 Methods of screening biological compounds 
1.5.4.1 Cytokine expression as a marker of inflammation 
Screening bioassays need to focus on an individual pathway (or pathways) affected by the 
treatment with extracts. These may include signal transduction, immune response, mitosis and 
apoptosis60. 
 
This project focused on the pro-inflammatory cytokines IL-1β and TNF-α for reasons discussed in 
section 1.2.2. Screening for modulation of IL-1β and TNF-α requires treatment of the THP-1 cells 
with a test compound/extract and measuring the expression of the cytokine by way of an enzyme-
linked immunoadsorbant assay (ELISA) 71. In particular the AlphaScreenELISA requires no 
washing of test plates making it ideal for high-throughput screening (see figure 1.5). 
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Figure 1.5 – Schematic depicting an AlphaScreenELISA  
The antigen being quantified in an AlphaScreenELISA is free (unbound) before being bound to a 
biotinylated antibody and an acceptor bead. The biotin is then bound to the streptavirdin-
conjugated donor bead before the immunefluorescence quantification takes place. Light at a 
wavelength of 680 nm is beamed into the solution causing an excitation and release of a single 
oxygen molecule which induces emission of light (615 nm) at the nearby acceptor bead. The 615 
nm light is read into to ELISA machine where it can be quantified. 
 
1.5.4.2 High throughput screening using signal transduction pathways 
A molecule deemed central to the inflammatory pathway in CRS is NF-κB. This signal transduction 
pathway is best quantified using a high-content image analysis from images taken via florescent 
microscopy (see figure 1.6). The p65 subunit of the NF-κB complex undergoes translocation when 
phosphorylated (activated) and this is the target of the immunostaining alone with a generic 
nucleus stain DAPI (see chapter 3 section 3.4). 
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Figure 1.6 – A schematic of the immunostaining of NF-κB for a quantitative 
immunoflorescent microscopy used in high-throughput screening. 
The p65 subunit of the NF-κB complex is bound by a polyclonal rabbit antibody (primary antibody) 
which is bound by goat-anti rabbit antibody conjugated with an immunofluorescent molecule. This 
undergoes excitation at 633 nm and emits light at 650-700 nm for quantification. This can occur in 
the nucleus or cytosol depending on the modulation of NF-κB by the treatment extract. DAPI stain 
is a non-specific nucleus counter stain that excited at 405 nm and emitted at 400-450 nm. The two 
different wavelengths are read and the crossover between their positions can be determined and 
quantified by the image analysis software. 
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1.5.5 Biological activity-guided fractionation for isolation of compounds 
 
Note: All fractionation was kindly donated by Professor Peter Parsons of the Queensland Institute 
for Medical Research (QIMR) - what follows is a summary of this process only. 
 
Once extracts have been selected (see section 1.5.5.2) it follows that purification and isolation of 
bioactive compounds requires fractionation. Fractionation is necessary in the field of drug 
discovery to isolate pure compounds and assess their activity against your selected bioassay as 
crude extracts may contain hundreds of differing compounds that may ultimately interact with your 
assay either synergistically or negatively. Once an active extract is located it is then fractionated 
and these subsequent fractions, termed “second generation fractions”, are also screened. The 
second generation is therefore more pure that the original extract and each fraction would have a 
mixture of compounds that would differ in solubility or polarity; depending on the method used to 
fractionate that generation. This process can be repeated until an active pure, or near pure mixture 
is reached. 
 
1.5.5.1 Crude extraction and solubility fractions 
Crude extracts are primary extracted using an alcohol solvent with finely blended organic material. 
Ethanol is the most commonly used solvent for this purpose72. Initial fractionation can occur by first 
air drying the crude extract and then re-diluting with solvents of varying polarity; commonly ethyl 
acetate, water, chloroform and hexane72. These fractions can then be re-dried and assayed for 
bioactivity. (See figure 1.7). 
 
Extracts need to be water-soluble as the media used for cell culture is predominantly water-based. 
If extracts are not soluble in water then dimethylsulfoxide (DMSO) may be used to break the 
thermodynamics of the extract first as a solvent72,73 
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Figure 1.7 – Overview of extraction and first fractionation of Ecobiotics™ extracts 
Four crude extracts from fruit and leaves were extracted using ethanol and water solution and 
dried. These were named 44, 45, 46 and 48. Extracts that showed activity in both IL-1β and NF-κB 
pathways by Phan et al73 were then dried and reconstituted in one of two solvents ethyl acetate or 
water. They were named E or W accordingly. 
 
Crude extracts from Ecobiotics™ were pre-screened by Phan et al73 using ethanol extraction and a 
bioassay for cytokine IL-1β and NF-κB translocation in THP-1 cells. 4 of these extracts were found 
to modulate both of these pathways and these dried crude extracts then underwent a secondary 
liquid extraction with ethyl acetate, then water, yielding two fractions for each crude extract. These 
first generation fractions are assessed in chapters 2 and 3 for IL-1β and TNF-α modulation and 
NF-κB translocation in THP-1 cells. (see figure 1.7). 
 
1.5.5.2 Silica gel column liquid chromatography fractionation 
First generation extracts (see 1.5.5.1) that have been assessed for bioactivity and show anti-
inflammatory properties in the AlphaScreenELISA (IL-1β and TNF-α) and translocation of NF-κB 
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assays are dried once more and fractioned using a silica gel column to perform liquid 
chromatography. Liquid chromatography uses the fractions solubility in various solvent 
concentrations to separate the fractions components74. (See figure 1.8). 
 
 
Figure 1.8 – Overview of second fractionation via silica gel liquid chromatography 
The mixture to be fractionated is placed in the silica gel of a glass column. Solvent mixtures of 
differing polarity, in this case petroleum ether, ethanol and methanol, are added with increasing 
polarity while the eluted mobile phase is collected from the bottom in aliquots named in this case 
fraction 1, 2 etc. 
 
During silica gel liquid chromatography, a form of column chromatography, silica gel is placed in a 
glass column, which is open at both ends. A small plug (usually wool) is placed at the bottom to 
stop the flow of the silica gel (solid phase) out of the column. The fraction is placed on top of the 
column and slowly liquid solvents are added (mobile phase). As they elute through the column they 
take portions of the fraction with them according to their solubility. Usually this mobile phase is 
done in parts with each part having a different concentration of solvent(s)75. (See figure 1.8). 
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For the purpose of this fraction the solvents used were petroleum spirit, ethyl acetate and 
methanol. The solvents are mixed into a number of solutions that increase in polarity and added to 
the silica column sequentially. Petroleum spirit has the lowest polarity followed by ethyl acetate and 
methanol76. Subsequently it can be deduced that fractions eluting from the column initially are 
hydrophobic and become more hydrophilic as the polarity of the solvent mix increases. 
 
 
1.5.5.3 High-performance liquid chromatography fractionation 
Bioactive fractions from the silica gel column chromatography are finally run through a secondary 
liquid chromatography. High-performance liquid chromatography (HPLC) uses a column with a 
solid phase (such as silica gel) and automated elution of solvents under pressure (up to 400 
atmospheres) to gain faster and more efficient fractionation77. Coupled to this some HPLC 
machines are able to concurrently analyse samples with ultraviolet (UV) spectrum, nuclear 
magnetic resonance (NMR) and infra-red spectrum (IR) analysis in order to help characterise 
fraction molecule make-ups77. (See figure 1.9). 
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Figure 1.9 – Overview of third fractionation via reverse-phase high performance liquid 
chromatography 
The mixture is placed into the HPLC column, which has a stationary gel phase consisting of non-
polar silica gel. The automated solvent delivery system then delivers solvents (in this case 
methanol and water) under high pressure to the column forcing the elution of fractions with 
increasing hydrophobicity. 
 
Two subtypes of HPLC exist; normal phased HPLC and reverse phased. Normal phase HPLC 
uses a polar solid phase (silica) and a non-polar solvent. The mobile phase passes through the 
column under pressure and the non-polar fractions will elute faster with the polar fractions sticking 
longer to the polar silica stationary phase77. The more commonly used method is reverse phase 
HPLC which uses a non-polar solid phase (silica with bound hydrocarbon chains) and a polar 
solvent such as water or methanol. In this method the more polar fractions would elute first77. 
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QIMR on behalf of the author uses reverse phase HPLC and a methanol-water solvent as a mobile 
phase. As a result the third generation fractions decrease in polarity as their number increases. 
(see figure 1.9). A profile of the HPLC fractionation as performed by QIMR can be seen in 
appendix 7.5. 
 
HPLC performed by the QIMR used concurrent NMR and mass spectrometry to guide selection of 
fractions that showed significant peaks or absorbance’s that were likely to represent a measurable 
concentration of compound(s). In this way the third generation screening is focused only on 
fractions with compounds present and not only solvent as might usually be the case. NMR-guided 
fractionation in HPLC is a concept that is used for this purpose in the literature78 though primarily it 
is used along with IR or mass spectrometry to identify the structure of compounds79. 
 
 
1.6 Summary 
CRS is a complex chronic inflammatory disease characterised by specific inflammatory profiles. 
Currently treatments for CRS focus on treating infections, which may precipitate attacks or steroids 
which dampen the inflammatory response. These treatments are not always effective and have 
side effects which necessitate further research and development of novel therapeutic targets. 
 
Drug discovery requires selection of therapeutic targets specific to the disease process such as 
pro-inflammatory cytokines IL-1β and TNF-α or signal transduction pathways like NF-κB. Pathways 
targeted dictate the bioassays that may be used while the disease process under scrutiny will 
dictate the cell-model used for screening possible therapeutics. Novel therapeutics can be 
synthesised or naturally occurring. The later requires extraction from a plant or animal source and 
screening through the bioassays for activity before purification via activity-based fractionation can 
take place. NMR, IR and UV spectrum absorbance may help describe active near-pure 
compounds. (See figure 1.10). 
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Figure 1.10 – A diagram illustrating the flow scheme for the bioactivity-guided fractionation 
of Ecobiotics™ extracts.  
Crude extracts are screened into either active or inactive groups and the active group is 
fractionated according to solubility in ethanol, ethyl acetate and water. These fractions are re-
screened and the active fractions are fractionated further using a silica column before being re-
screened. Active fractions are then run through a final fractionation process involving a high-
performance liquid chromatography before being screened for activity. Active near-pure isolates 
can then be identified using NMR or similar absorbance’s. 
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1.7 Hypothesis and aims 
1.7.1 Hypothesis 
Ecobiotics™ extracts undergoing bioactivity-guided investigation will modulate cytokines IL-1β and 
TNF-α and inhibit NF-κB translocation in PMA-differentiated THP-1 cells. 
 
1.7.2 Aims 
1. Use bioactivity-guided fractionation to isolate pure, active compounds from previously screened 
Ecobiotics™ crude extracts. 
 
2. Using AlphaScreenELISA and quantitative fluorescent microscopy in high-throughput screening 
to determine bioactivity against cytokines IL-1β, TNF-α as well as signal transduction molecule NF-
κB in PMA-differentiated THP-1 cells. 
 
3. Determine cell viability of treated THP-1 cells using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) tetrazolium assay to determine extract toxicity.  
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Chapter 2  
Activity guided investigation of the bioactivity of Ecobiotics™ extracts 
using immunofluorescence to quantify cytokines IL-1β and TNF-α 
modulation in LPS-stimulated, PMA-differentiated human monocytes 
 
2.1 Foreword 
Outlined in this chapter is the role of cytokines IL-1β and TNF-α in CRS and as such their 
attractiveness as therapeutic targets. Bioactivity against these cytokines may indicate efficacy for 
chronic inflammatory conditions such as CRS. This chapter will look at modulation of these 
cytokines to guide fractionation and hence purification of biological extracts. 
 
 
2.2 Introduction 
IL-1β and TNF-α are considered pro-inflammatory cytokines and are released in acute phase 
response to sepsis, injury or hypoxia. As outlined in chapter 1.3.5 these two cytokines promote 
each others release in the acute phase response and act together to modulate the immune 
response80. In a THP-1 cell system using LPS as a biological stimulant to promote an inflammatory 
response the biological extract fractions can be screened for modulation of these two cytokine 
expressions. Due to the intertwined nature of their acute phase response and co-activity through 
NF-κB pathway the expectation is that predominantly the responses will mirror each other. When 
responses do not mirror each other this may indicate a separate secondary signal transduction 
pathway other than NF-κB.  
 
The AlphaScreenELISA uses antibodies against the cytokines to effectively label them with a 
florescent enzyme. This enzyme allows detection at a specific wavelength of light (see chapter 
1.5.4.1). This unique assay allows testing of two samples of the same treatment supernatant 
against two separate cytokines (TNF-α and IL-1β). 
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2.2.1 Quantification of cytokines in biological systems 
Many assays exist that can quantify cytokine levels in biological systems. Detection of a specific 
cytokine necessitates an understanding of its characteristics, most importantly the half life. While 
the half life of many cytokines is extremely short a few exceptions exist for which IL-1β and TNF-α 
are among80. The type of assay chosen to measure cytokine production could be a bioassay, 
enzyme-linked immunosorbent assay (ELISA), intracellular staining assay or reverse transcriptase-
polymerase chain reaction (RT-PCR) and real-time PCR80. 
 
The specific requirements of high-throughput screening eliminates the standard bioassay which, 
although sensitive, is extremely labour intensive while the PCR detects transcription only and not 
secreted protein80. The ELISA is both specific and fast allowing rapid detection in larger scale 
experiments important in high-throughput screening80. This experiment made use of the 
AlphaScreenELISA with antibodies against TNF-α and IL-1β. 
 
 
2.3 Materials and Methods 
2.3.1 Culturing THP-1 cells and differentiation 
THP-1 cells, a gift from Associate Professor Marie-Odile Parat (School of Pharmacy, University of 
Queensland, Brisbane, Australia), were cultured in RPMI 1640 with 10% FBS and 1% 
penicillin/streptomycin (Invitrogen, Mulgrave, Victoria). Once cell flasks reached 80% confluency 
(estimated) at approximately day 5-6 the cells were split into fresh media containing RPMI 1640 
with 10% FBS and 1% penicillin/streptomycin at 1.5:10 ratio. Cells were cultured in T-75 cm2 flasks 
with incubator settings of 37 °C, 5% humidified CO2. Subculturing was limited to passage numbers 
of less than 25. 
 
THP-1 cells that were around 80% confluent underwent centrifugation at room temperature (200 g 
for 6 minutes) and supernatant was then discarded while the cell pellet was re-suspended in RPMI 
1640 with 10% FBS and 1% penicillin/streptomycin at 37°C. A haemocytometer was used to 
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quantify a cell counts using trypan blue exclusion stain. The cell suspension was then exposed to 
toa 50 nM solution of PMA (previously optimised – Axxora distributing for Sapphire Biosciences, 
Redfern, NSW) to allow for monocyte differentiation into macrophages.  
 
For these experiments a cells/well density of 200,000 were seeded into 96 well plates then 
incubated at 37°C in humidified 5% C02 for 48 hours. At 48 hours the wells were inspected, 
excluding poorly confluent wells and media aspirated ready for treatment. 
 
2.3.2 Preparation of samples 
Four initial crude extracts deemed active in modulating IL-1β and NF-κB by Phan et al13 were 
kindly provided by Ecobiotics™ and fractionated by QIMR laboratories on behalf of the author. 
These fractions were dried and weighed following the first fractionation, which allowed accurate 
reconstitution in sterile DMSO alone. Second and third generation extracts were in too small 
volumes to accurately weigh so the dried fractions were reconstituted in 50 µL of sterile DMSO 
each so as to accurately compare across fractions of the same generation. 
 
2.3.3 Treating differentiated THP-1 cells 
Treatment occurred in warmed media containing RPMI 1640 with 1% FBS and with the exception 
of the negative control, supplemented with 0.1µL/mL (previously optimised, Enzo Life Sciences, 
New York, USA). Treatments were added to the wells in volumes of 100µL/well in triplicate and all 
plates contained both a negative (media with DMSO) and positive (media with LPS) control along 
with the treatments. Plates were then incubated at 37°C in humidified 5% C02 for 24 hours.  
 
Wells were individually placed into eppendorf tubes and centrifuged at 6000g, 4°C for 20 min 
before the supernatant was removed and placed into fresh eppendorf tube and frozen at -80°C 
until AlphaScreenELISA could be performed. 
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2.3.4 AlphaScreenELISA 
As discussed in chapter 1.5.4.1 both IL-1β and TNF-α levels in supernatant will be quantified using 
AlphaScreenELISA (Perkin Elmer, Rowville, Vitoria, Australia). The standard curves for both IL-1β 
and TNF-α were prepared as per appendix 2 with serial dilutions using RMPI 1640 with 1% FBS. 
The IL-1β standard curve provides a concentration range of 1 x 10-8 to 3 x 10-13 while TNF-α 
ranges from 1 x 10-7 to 3 x 10-12 (previously optimised). 
 
Treatments along with the standard curve dilutions were added in volumes of 1 µL each, and in 
duplicate, to a 384 well plate (Perkin Optiplate-384). Immunoassay buffer (see appendix 4) 
containing anti-IL-1β conjugated to acceptor beads (5 mg/mL) or anti-TNF-α conjugated to 
acceptor beads (5 mg/mL) along with biotinylated antibody at 500 nM is added to each well at a 
volume of 4 µL. Plates were incubated at room temperature in low light conditions for one hour with 
slow shaking. 
 
After one hour of incubation streptavidin donor beads are added (specific to either IL-1β or TNF-α) 
at a concentration of 80 µg/mL in immunoassay buffer and a volume of 5 µL/well. Plates were then 
further incubated at room temperature, in low light conditions with slow shaking for 30 minutes 
before being read by the Enspire-Alpha 2390 Multilabel Plate Reader (Perkin Elmer, Australia). 
 
 
2.3.5 Data analysis 
Data is presented as mean ± SEM and significance is demonstrated using one-way analysis of 
variance (ANOVA); p < 0.05. Post-hoc testing was carried out using Bonferoni’s test for multiple 
comparisons comparing the positive control (media with LPS) verses treatments. 
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2.4 Results 
2.4.1 First generation fractions of biological extracts modulate expression of pro-
inflammatory cytokines IL-1β and TNF-α in PMA-differentiated THP-1 cells 
Eight fractions were taken from four active extracts assessed by Phan et al73. They were named 
44W, 44E, 45W, 45E, 46W, 46E, 47W and 47E (see figure 2.1) 
 
Name of active crude extract 
(Phan et al73) 
Solubility of fraction Name of first generation 
treatment 
BE11 Water 44W 
 Ethyl Acetate 44E 
BE37 Water 45W 
 Ethyl Acetate 45E 
BE41 Water 46W 
 Ethyl Acetate 46E 
BE43 Water 47W 
 Ethyl Acetate 47E 
 
Figure 2.1 – Nomenclature and crude-extract origins of first generation fractions. 
Four bioactive crude extracts taken from Phan et al73 named BE11, BE37, BE41 and BE43 were 
fractionated according to solubility by ethyl acetate or water. They are named sequentially from 44-
47 with “W” signifying a water-soluble fraction and “E” signifying ethyl acetate solubility. 
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Figure 2.2 – 44W modulates cytokine IL-1β and TNF-α expression in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of 44W were added to PMA-differentiated THP-1 cells. 44W 
stimulates IL-1β release. (B) LPS and various concentrations of 44W were added to PMA-
differentiated THP-1 cells. 44W modulates TNF-α release. Data is presented as mean ± SEM 
where n = 3 (represents 3 independent experiments). 
 
44W significantly stimulates cytokine IL-1β release concentrations of 1 x 10-4 % w/v, 1 x 10-6 % w/v 
and 1 x 10-8 % w/v (see 2.2A - 1 x 10-4 108.7 ± 4.3, 1 x 10-6 118.0 ± 7.5, 1 x 10-8 109.4 ± 4.4). 44W 
modulated cytokine TNF-α by first inhibiting at 1 x 10-4 % w/v then stimulating at 1 x 10-8 % w/v 
(see figure 2.2B - 1 x 10-4 78.61 ± 7.9, 1 x 10-8 149.5 ± 15.3). 
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Figure 2.3 – 44E modulates cytokine IL-1β and TNF-α expression in PMA-differentiated THP-
1 cells 
(A) LPS and various concentrations of 44E were added to PMA-differentiated THP-1 cells. 44E 
modulates IL-1β release. (B) LPS and various concentrations of 44E were added to PMA-
differentiated THP-1 cells. 44E inhibits TNF-α release. Data is presented as mean ± SEM where n 
= 3 (represents 3 independent experiments). 
 
44E significantly modulates cytokine IL-1β release first inhibiting strongly at a concentrations of 1 x 
10-4 % w/v then promoting its release at 1 x 10-8 % w/v and 1 x 10-10 % w/v (see 2.3A - 1 x 10-4 
24.28 ± 7.9, 1 x 10-8 121.2 ± 4.6, 1 x 10-10 120.2 ± 6.1). 44E inhibited cytokine TNF-α release at 
concentrations 1 x 10-4 % w/v, 1 x 10-6 % w/v and 1 x 10-8 % w/v (see figure 2.3B - 1 x 10-4 79.8 ± 
3.5, 1 x 10-6 79.8 ± 7.0, 1 x 10-8 76.2 ± 5.3). 
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Figure 2.4 – 45W modulates cytokine IL-1β and TNF-α expression in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of 45W were added to PMA-differentiated THP-1 cells. 45W 
stimulates IL-1β release. (B) LPS and various concentrations of 45W were added to PMA-
differentiated THP-1 cells. 45W inhibits TNF-α release. Data is presented as mean ± SEM where n 
= 3 (represents 3 independent experiments). 
 
45W significantly stimulates cytokine IL-1β release at concentrations of 1 x 10-6 % w/v, 1 x 10-8 % 
w/v and 1 x 10-10 % w/v (see 2.4A - 1 x 10-6 110.3 ± 5.2, 1 x 10-8 116.4 ± 4.2, 1 x 10-10 114.1 ± 3.4). 
45W inhibited cytokine TNF-α release one concentration of 1 x 10-6 % w/v only (see figure 2.4B - 1 
x 10-5 63.7 ± 5.9). 
  
 49 
 
 
A 
 
 
 
B 
 
 
  
DM
SO
 C
on
tro
l
LP
S C
on
tro
l 
45
E [
10
-4 ]
45
E [
10
-6 ]
45
E [
10
-8 ]
45
E [
10
-10
]
0
50
100
150
45E stimulates IL-1β release 
 
Treatment (%)
IL
-1
β
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗ ∗ ∗
DM
SO
 C
on
tro
l
LP
S C
on
tro
l 
45
E [
10
-4 ]
45
E [
10
-6 ]
45
E [
10
-8 ]
45
E [
10
-10
]
0
100
200
300
45E stimulates TNF-α release 
 
Treatment (%)
TN
F-
α
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗
∗
 50 
Figure 2.5 – 45E modulates cytokine IL-1β and TNF-α expression in PMA-differentiated THP-
1 cells 
(A) LPS and various concentrations of 45E were added to PMA-differentiated THP-1 cells. 45E 
stimulates IL-1β release. (B) LPS and various concentrations of 45E were added to PMA-
differentiated THP-1 cells. 45E stimulates TNF-α release. Data is presented as mean ± SEM 
where n = 3 (represents 3 independent experiments). 
 
45E significantly stimulates cytokine IL-1β release at concentrations of 1 x 10-6 % w/v, 1 x 10-8 % 
w/v and 1 x 10-10 % w/v (see 2.5A - 1 x 10-6 121.9 ± 4.5, 1 x 10-8 109.3 ± 5.9, 1 x 10-10 111.0 ± 4.6). 
45E strongly stimulated cytokine TNF-α release at 1 x 10-4 % w/v and 1 x 10-6 % w/v only (see 
figure 2.5B - 1 x 10-4 128.7 ± 9.8, 1 x 10-6 248.8 ± 19.9). 
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Figure 2.6 – 46W modulates cytokine IL-1β and TNF-α expression in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of 46W were added to PMA-differentiated THP-1 cells. 46W 
stimulates IL-1β release. (B) LPS and various concentrations of 46W were added to PMA-
differentiated THP-1 cells. 46W does not modulate TNF-α release. Data is presented as mean ± 
SEM where n = 3 (represents 3 independent experiments). 
 
46W significantly stimulates cytokine IL-1β release at concentrations of 1 x 10-4 % w/v and 1 x 10-6 
% w/v (see 2.6A - 1 x 10-4 108.8 ± 3.5, 1 x 10-6 114.4 ± 3.7). 46W did not modulate TNF-α release 
(see figure 2.6B). 
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Figure 2.7 – 46E stimulates cytokine IL-1β and TNF-α expression in PMA-differentiated THP-
1 cells 
(A) LPS and various concentrations of 46E were added to PMA-differentiated THP-1 cells. 46E 
stimulates IL-1β release. (B) LPS and various concentrations of 46E were added to PMA-
differentiated THP-1 cells. 46E stimulates TNF-α release. Data is presented as mean ± SEM 
where n = 3 (represents 3 independent experiments). 
 
46E significantly stimulates cytokine IL-1β release in all concentrations (see 2.7A - 1 x 10-4 188.0 ± 
5.4, 1 x 10-6 156.2 ± 3.4, 1 x 10-8 114.6 ± 2.9, 1 x 10-10 110.4 ± 2.1). 46E strongly stimulated 
cytokine TNF-α release at 1 x 10-4 % w/v, 1 x 10-6 % w/v and 1 x 10-8 % w/v (see figure 2.7B - 1 x 
10-4 203.7 ± 3.0, 1 x 10-6 161.6 ± 3.5, 1 x 10-8 117.2 ± 1.9). 
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Figure 2.8 – 47W stimulates cytokine IL-1β and TNF-α expression in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of 47W were added to PMA-differentiated THP-1 cells. 47W 
stimulates IL-1β release. (B) LPS and various concentrations of 47W were added to PMA-
differentiated THP-1 cells. 47W stimulates TNF-α release. Data is presented as mean ± SEM 
where n = 3 (represents 3 independent experiments). 
 
47W significantly stimulates cytokine IL-1β release in all concentrations (see 2.8A - 1 x 10-4 158.1 
± 4.0, 1 x 10-6 130.7 ± 3.7, 1 x 10-8 119.1 ± 3.1, 1 x 10-10 118.3 ± 3.2). 47W stimulated cytokine 
TNF-α release in all concentrations (see figure 2.8B - 1 x 10-4 163.8 ± 5.1, 1 x 10-6 130.7 ± 3.7, 1 x 
10-8 120.9 ± 2.8, 1 x 10-10 120.9 ± 2.4). 
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Figure 2.9 – 47E stimulates cytokine IL-1β and TNF-α expression in PMA-differentiated THP-
1 cells 
(A) LPS and various concentrations of 47E were added to PMA-differentiated THP-1 cells. 47E 
stimulates IL-1β release. (B) LPS and various concentrations of 47E were added to PMA-
differentiated THP-1 cells. 47E stimulates TNF-α release. Data is presented as mean ± SEM 
where n = 3 (represents 3 independent experiments). 
 
47E significantly stimulates cytokine IL-1β release in concentrations of 1 x 10-6 % w/v, 1 x 10-8 % 
w/v and 1 x 10-10 % w/v (see 2.9A - 1 x 10-6 117.3 ± 4.5, 1 x 10-8 116.1 ± 5.6, 1 x 10-10 107.7 ± 3.6). 
47E stimulated cytokine TNF-α release in concentrations of 1 x 10-6 % w/v, 1 x 10-8 % w/v and 1 x 
10-10 % w/v (see figure 2.9B - 1 x 10-6 121.9 ± 3.4, 1 x 10-8 124.7 ± 4.1, 1 x 10-10 117.2 ± 2.9). 
 
 
2.4.2 Second generation fractions of biological extracts modulate expression of pro-
inflammatory cytokines IL-1β and TNF-α in PMA-differentiated THP-1 cells 
Outlined in figure 1.4 is the process of fractionating the selected ethyl acetate-soluble fraction of 
extract 44 which was shown to be significantly inhibitory for the release of cytokines TNF–α and IL-
1β (see chapter 2) as well as inhibiting translocation of NF-κB. This fractionation process revealed 
22 second-generation fractions, which were prepared as per section 1.5.5.2 (see figure 2.10) and 
underwent testing for modulation of NF-κB translocation in PMA-differentiated THP-1 cells. The 
results of these second generation fractions are reported below along with the load; which 
represents the unfractionated sample. 
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Figure 2.10 – Nomenclature of fractions of active first-generation fraction 44E. 
Selected active first-generation fraction 44E is fractionated by silica gel liquid chromatography to 
yield 22 sub-fractions (second-generation fractions) named F1 through to F22. The silica column is 
applied with 11 different solvent mixes each mixture containing 4mL. As the mixtures are applied in 
order the fractions elute from the bottom of the column. Each fraction represents 2mL of eluted 
fluid and as such 11 solvent mixtures yield 22 sub-fractions. Table is partially reproduced from 
QIMR laboratory. Author was not involved with this fractionation process. 
 
 
Solvent Mix Petroleum Spirit Ethyl Acetate Methanol Fraction name 
1 3.556mL 0.444mL 0mL F1 & F2 
2 3mL 1mL 0mL F3 & F4 
3 2.66mL 1.33mL 0mL F5 & F6 
4 2mL 2mL 0mL F7 & F8 
5 1.33mL 2.66mL - F9 & F10 
6 1mL 3mL - F11 & F12 
7 - 4mL - F13 & F14 
8 - 3.96mL 0.04mL F15 & F16 
9 - 3.8mL 0.2mL F17 & F18 
10 - 3.6mL 0.4mL F19 & F20 
11 - - 4mL F21 & F22 
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Figure 2.11 – F1 fraction of 44E stimulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F1 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F1 does not IL-1β release. (B LPS and various concentrations of the F1 fraction of 
44E were added to PMA-differentiated THP-1 cells. F1 stimulates TNF-α release. Data is 
presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F1 fraction of 44E does not modulate cytokine IL-1β (see 2.11A). F1 fraction of 44E stimulated 
cytokine TNF-α release in concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v (see figure 2.11B - 1 
x 10-4 127.6 ± 5.0, 1 x 10-6 126.0 ± 5.4). 
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Figure 2.12 – F2 fraction of 44E inhibits cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F2 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F2 inhibits IL-1β release. (B LPS and various concentrations of the F2 fraction of 44E 
were added to PMA-differentiated THP-1 cells. F2 inhibits TNF-α release. Data is presented as 
mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F2 fraction of 44E inhibits cytokine IL-1β in concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v 
(see 2.12A - 1 x 10-4 24.3 ± 7.9, 1 x 10-6 73.2 ± 7.7). F2 fraction of 44E stimulated cytokine TNF-α 
release in the highest concentrations of 1 x 10-4 % w/v (see figure 2.12B - 1 x 10-4 44.8 ± 4.0). 
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Figure 2.13 – F3 fraction of 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F3 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F3 does not modulate IL-1β release. (B LPS and various concentrations of the F3 
fraction of 44E were added to PMA-differentiated THP-1 cells. F3 inhibits TNF-α release. Data is 
presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F3 fraction of 44E does not modulate cytokine IL-1β (see 2.13A. F3 fraction of 44E inhibits 
cytokine TNF-α release in the highest concentrations of 1 x 10-4 % w/v (see figure 2.13B - 1 x 10-4 
78.6 ± 7.8). 
  
 66 
 
 
A 
 
 
 
B 
 
 
  
DM
SO
 C
on
tro
l
LP
S C
on
tro
l
F4
 [1
0-
4 ]
F4
 [1
0-
6 ]
F4
 [1
0-
8 ]
F4
 [1
0-
10 ]
0
50
100
150
F4 fraction of 44E inhibits 
IL-1β release
Treatment (%)
IL
-1
β
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗
DM
SO
 C
on
tro
l
LP
S C
on
tro
l
F4
 [1
0-
4 ]
F4
 [1
0-
6 ]
F4
 [1
0-
8 ]
F4
 [1
0-
10 ]
0
50
100
150
F4 fraction of 44E inhibits
TNF-α release
Treatment (%)
TN
F-
α
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗
∗
 67 
Figure 2.14 – F4 fraction of 44E inhibits cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F4 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F4 inhibits IL-1β release. (B LPS and various concentrations of the F4 fraction of 44E 
were added to PMA-differentiated THP-1 cells. F4 inhibits TNF-α release. Data is presented as 
mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F4 fraction of 44E inhibits cytokine IL-1β in the highest concentrations of 1 x 10-4 % w/v  (see 
2.14A - 1 x 10-4 67.8 ± 8.9). F4 fraction of 44E inhibited cytokine TNF-α release in concentrations 
of 1 x 10-4 % w/v and 1 x 10-6 % w/v (see 2.14B - 1 x 10-4 65.9 ± 8.2, 1 x 10-6 79.3 ± 7.1). 
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Figure 2.15 – F5 fraction of 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F5 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F5 does not modulate IL-1β release. (B LPS and various concentrations of the F5 
fraction of 44E were added to PMA-differentiated THP-1 cells. F5 inhibits TNF-α release. Data is 
presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F5 fraction of 44E does not modulate cytokine IL-1β release (see 2.15A). F5 fraction of 44E 
inhibited cytokine TNF-α release in concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v (see 2.15B 
- 1 x 10-4 36.1 ± 2.7, 1 x 10-6 76.6 ± 3.1). 
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Figure 2.16 – F6 fraction of 44E modulate cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F4 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F4 inhibits IL-1β release. (B LPS and various concentrations of the F4 fraction of 44E 
were added to PMA-differentiated THP-1 cells. F4 inhibits TNF-α release. Data is presented as 
mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F4 fraction of 44E inhibits cytokine IL-1β in the highest concentrations of 1 x 10-4 % w/v  (see 
2.16A - 1 x 10-4 67.8 ± 8.9). F4 fraction of 44E inhibited cytokine TNF-α release in concentrations 
of 1 x 10-4 % w/v and 1 x 10-6 % w/v (see 2.16B - 1 x 10-4 65.9 ± 8.2, 1 x 10-6 79.3 ± 7.1). 
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Figure 2.17 – F7 fraction of 44E modulate cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F7 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F7 stimulates IL-1β release. (B) LPS and various concentrations of the F7 fraction of 
44E were added to PMA-differentiated THP-1 cells. F4 inhibits TNF-α release. Data is presented 
as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F7 fraction of 44E stimulates cytokine IL-1β in the highest concentrations of 1 x 10-4 % w/v  (see 
2.17A - 1 x 10-4 146.7 ± 5.9). F7 fraction of 44E inhibited cytokine TNF-α release in the highest 
concentrations of 1 x 10-4 % w/v  (see 2.17B - 1 x 10-4 76.4 ± 4.1). 
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Figure 2.18 – F8 fraction of 44E modulate cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F8 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F8 does not mosulate IL-1β release. (B) LPS and various concentrations of the F8 
fraction of 44E were added to PMA-differentiated THP-1 cells. F8 inhibits TNF-α release. Data is 
presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F8 fraction of 44E does not modulate cytokine IL-1β (see 2.18A). F6 fraction of 44E inhibited 
cytokine TNF-α release in the highest concentrations of 1 x 10-4 % w/v  (see 2.18B - 1 x 10-4 45.3 ± 
3.4). 
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Figure 2.19 – F9 fraction of 44E modulate cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F9 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F9 inhibits IL-1β release. (B) LPS and various concentrations of the F9 fraction of 44E 
were added to PMA-differentiated THP-1 cells. F9 inhibits TNF-α release. Data is presented as 
mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F9 fraction of 44E inhibited cytokine IL-1β release in the highest concentration of 1 x 10-4 % w/v 
(see 2.19A - 1 x 10-4 70.6 ± 6.1). F9 fraction of 44E inhibited cytokine TNF-α release in the highest 
concentration of 1 x 10-4 % w/v  (see 2.19B - 1 x 10-4 55.2 ± 2.7). 
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Figure 2.20 – F10 fraction of 44E inhibits cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F10 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F10 inhibits IL-1β release. (B) LPS and various concentrations of the F10 fraction of 
44E were added to PMA-differentiated THP-1 cells. F10 inhibits TNF-α release. Data is presented 
as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F10 fraction of 44E inhibited cytokine IL-1β release in the highest concentration of 1 x 10-4 % w/v 
(see 2.20A - 1 x 10-4 73.6 ± 7.2). F10 fraction of 44E inhibited cytokine TNF-α release in the 
highest concentration of 1 x 10-4 % w/v  (see 2.20B - 1 x 10-4 54.8 ± 2.6). 
  
 80 
 
 
A 
 
 
 
B 
 
 
  
DM
SO
 C
on
tro
l
LP
S C
on
tro
l
F1
1 [
10
-4 ]
F1
1 [
10
-6 ]
F1
1 [
10
-8 ]
F1
1 [
10
-10
]
0
50
100
150
F11 fraction of 44E does not 
modulate IL-1β release
Treatment (%)
IL
-1
β
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
DM
SO
 C
on
tro
l
LP
S C
on
tro
l
F1
1 [
10
-4 ]
F1
1 [
10
-6 ]
F1
1 [
10
-8 ]
F1
1 [
10
-10
]
0
50
100
150
F11 fraction of 44E does not
modulate TNF-α release
Treatment (%)
TN
F-
α
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
 81 
Figure 2.21 – F11 fraction of 44E does not modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the F11 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F11 does not modulate IL-1β release. (B) LPS and various concentrations of the F11 
fraction of 44E were added to PMA-differentiated THP-1 cells. F11 does not modulate TNF-α 
release. Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F11 fraction of 44E does not modulate cytokine IL-1β release (see 2.21A). F11 fraction of 44E 
does not modulate cytokine TNF-α release (see 2.21B). 
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Figure 2.22 – F12 fraction of 44E modulate cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F12 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F12 does not modulate IL-1β release. (B) LPS and various concentrations of the F12 
fraction of 44E were added to PMA-differentiated THP-1 cells. F12 inhibits TNF-α release. Data is 
presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F12 fraction of 44E did not modulate cytokine IL-1β release (see 2.22A). F12 fraction of 44E 
inhibited cytokine TNF-α release in the highest concentration of 1 x 10-4 % w/v  (see 2.22B - 1 x 10-
4 80.1 ± 2.6). 
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Figure 2.23 – F13 fraction of 44E modulate cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F13 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F13 does not modulate IL-1β release. (B) LPS and various concentrations of the F13 
fraction of 44E were added to PMA-differentiated THP-1 cells. F13 modulates TNF-α release. Data 
is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F13 fraction of 44E did not modulate cytokine IL-1β release (see 2.23A). F13 fraction of 44E 
inhibited cytokine TNF-α release in the highest concentration of 1 x 10-4 % w/v and stimulated the 
release at 1 x 10-8 % w/v (see 2.23B - 1 x 10-4 84.5 ± 5.9, 1 x 10-8 117.3 ± 3.1). 
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Figure 2.24 – F14 fraction of 44E does not modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the F14 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F14 does not modulate IL-1β release. (B) LPS and various concentrations of the F14 
fraction of 44E were added to PMA-differentiated THP-1 cells. F14 does not modulate TNF-α 
release. Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F14 fraction of 44E did not modulate cytokine IL-1β release (see 2.24A). F13 fraction of 44E did 
not modulate cytokine TNF-α (see 2.24B). 
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Figure 2.25 – F15 fraction of 44E modulate cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F15 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F15 does not modulate IL-1β release. (B) LPS and various concentrations of the F15 
fraction of 44E were added to PMA-differentiated THP-1 cells. F15 stimulates TNF-α release. Data 
is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F15 fraction of 44E did not modulate cytokine IL-1β release (see 2.25A). F15 fraction of 44E 
stimulates cytokine TNF-α release in the highest concentration of 1 x 10-4 % w/ (see 2.25B - 1 x 10-
4 113.6 ± 2.9). 
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Figure 2.26 – F16 fraction of 44E does not modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the F16 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F16 does not modulate IL-1β release. (B) LPS and various concentrations of the F16 
fraction of 44E were added to PMA-differentiated THP-1 cells. F16 does not modulate TNF-α 
release. Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F16 fraction of 44E did not modulate cytokine IL-1β release (see 2.26A). F16 fraction of 44E does 
not modulate cytokine TNF-α release (see 2.26B). 
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Figure 2.27 – F17 fraction of 44E inhibits cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F17 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F17 inhibits IL-1β release. (B) LPS and various concentrations of the F17 fraction of 
44E were added to PMA-differentiated THP-1 cells. F17 inhibits TNF-α release. Data is presented 
as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F17 fraction of 44E inhibits cytokine IL-1β release at a concentration of 1 x 10-8 % w/v. (see 2.27A - 
1 x 10-8 79.4 ± 3.0). F17 fraction of 44E inhibits cytokine TNF-α release in all but the highest 
concentration of 1 x 10-4 % w/v (see 2.27B - 1 x 10-6 71.3 ± 3.9, 1 x 10-8 80.6 ± 5.3, 1 x 10-10 80.6 ± 
3.2). 
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Figure 2.28 – F18 fraction of 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F18 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F18 stimulates IL-1β release. (B) LPS and various concentrations of the F18 fraction 
of 44E were added to PMA-differentiated THP-1 cells. F18 does not modulate TNF-α release. Data 
is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F18 fraction of 44E stimulates cytokine IL-1β release at a concentration of 1 x 10-4 % w/v. (see 
2.28A - 1 x 10-4 122.5 ± 5.4). F18 fraction of 44E does not modulate cytokine TNF-α release (see 
2.28B). 
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Figure 2.29 – F19 fraction of 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F19 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F19 stimulated IL-1β release. (B) LPS and various concentrations of the F19 fraction 
of 44E were added to PMA-differentiated THP-1 cells. F19 inhibits TNF-α release. Data is 
presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F19 fraction of 44E stimulates cytokine IL-1β release at concentrations of 1 x 10-8 % w/v and 1 x 
10-10 % w/v. (see 2.29A - 1 x 10-8 138.1 ± 12.5, 1 x 10-10 124.7 ± 9.2). F19 fraction of 44E inhibits 
cytokine TNF-α release in all concentrations (see 2.29B - 1 x 10-4 85.0 ± 6.8, 1 x 10-6 79.7 ± 4.6, 1 
x 10-8 79.7 ± 9.6, 1 x 10-10 76.4 ± 4.2). 
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Figure 2.30 – F20 fraction of 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F20 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F20 did not modulate IL-1β release. (B) LPS and various concentrations of the F20 
fraction of 44E were added to PMA-differentiated THP-1 cells. F20 inhibits TNF-α release. Data is 
presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F20 fraction of 44E does not modulate cytokine IL-1β release. (see figure 2.30A). F20 fraction of 
44E inhibits cytokine TNF-α release in all concentrations (see figure 2.30B - 1 x 10-4 69.8 ± 5.2, 1 x 
10-6 59.3 ± 6.3, 1 x 10-8 85.4 ± 5.7, 1 x 10-10 74.9 ± 4.6). 
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Figure 2.31 – F21 fraction of 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F21 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F21 modulates IL-1β release. (B) LPS and various concentrations of the F21 fraction 
of 44E were added to PMA-differentiated THP-1 cells. F21 does not modulate TNF-α release. Data 
is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F21 fraction of 44E stimulates cytokine IL-1β release at 1 x 10-4 % w/v then inhibits at 1 x 10-8 % 
w/v (see 2.31A - 1 x 10-4 139.7 ± 11.3, 1 x 10-8 65.4 ± 8.3). F21 fraction of 44E does not modulate 
cytokine TNF-α (see 2.31B). 
  
 102 
 
 
A 
 
 
 
B 
 
 
  
DM
SO
 C
on
tro
l
LP
S C
on
tro
l
F2
2 [
10
-4 ]
F2
2 [
10
-6 ]
F2
2 [
10
-8 ]
F2
2 [
10
-10
]
0
50
100
150
200
250
F22 fraction of 44E stimulates 
IL-1β release
Treatment (%)
IL
-1
β
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗
∗
DM
SO
 C
on
tro
l
LP
S C
on
tro
l
F2
2 [
10
-4 ]
F2
2 [
10
-6 ]
F2
2 [
10
-8 ]
F2
2 [
10
-10
]
0
50
100
150
F22 fraction of 44E inhibits
TNF-α release
Treatment (%)
TN
F-
α
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗∗
 103 
Figure 2.32 – F22 fraction of 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F22 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F22 stimulates IL-1β release. (B) LPS and various concentrations of the F22 fraction 
of 44E were added to PMA-differentiated THP-1 cells. F22 inhibits TNF-α release. Data is 
presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F22 fraction of 44E stimulates cytokine IL-1β release at 1 x 10-4 % w/v and 1 x 10-6 % w/v (see 
2.32A - 1 x 10-4 139.7 ± 11.3, 1 x 10-6 93.1 ± 8.0). F22 fraction of 44E inhibits cytokine TNF-α at 
concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v (see 2.32B - 1 x 10-4 85.8 ± 3.2, 1 x 10-6 82.2 ± 
3.3). 
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Figure 2.33 – Load fraction of 44E modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the load fraction of 44E were added to PMA-differentiated 
THP-1 cells. The load modulates IL-1β release. (B) LPS and various concentrations of the load 
fraction of 44E were added to PMA-differentiated THP-1 cells. The load inhibits TNF-α release. 
Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
Load fraction of 44E inhibits cytokine IL-1β release at 1 x 10-4 % w/v and stimulates at 1 x 10-6 % 
w/v and 1 x 10-8 % w/v (see 2.33A - 1 x 10-4 63.2 ± 2.9, 1 x 10-6 119.9 ± 12.9, 1 x 10-8 136.4 ± 
14.6). Load fraction of 44E inhibits cytokine TNF-α at all concentrations (see 2.33B - 1 x 10-4 66.6 ± 
4.1, 1 x 10-6 85.9 ± 3.9, 1 x 10-8 85.9 ± 4.6, 1 x 10-10 85.8 ± 3.2). 
 
 
2.4.3 Third generation fractions of biological extracts modulate expression of pro-
inflammatory cytokines IL-1β and TNF-α in PMA-differentiated THP-1 cells 
Outlined in section 1.5.5.3 is the process of fractionating the selected second-generation fraction of 
F2. F2 was shown to significantly reduce the release of cytokines TNF–α and IL-1β as well as 
inhibiting translocation of NF-κB (see figure 3.5B).  
 
Fractionation using the HPLC reverse phase method for F2 using a methanol and water solvent 
mix yielded 29 sub-fractions (third generation fractions) which are named H1 through to H29. 
These fractions become more hydrophilic as the number increases (see section 1.5.5.3). 29 
fractions plus a load fraction that represents an unfractionated sample underwent testing for 
modulation of NF-κB translocation in PMA-differentiated THP-1 cells. The results of H1 to H29 
fractions and the load are reported below.  
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Figure 2.34 – H1 fraction of F2 does not modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the H1 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H1 does not modulate IL-1β release. (B) LPS and various concentrations of the H1 
fraction of F2 were added to PMA-differentiated THP-1 cells. H1 does not modulate TNF-α release. 
Data is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H1 fraction of F2 does not modulate cytokine IL-1β release (see 2.34A). The H1 fraction of F2 
does not modulate cytokine TNF-α (see 2.34B). 
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Figure 2.35 – H2 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H2 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H2 modulates IL-1β release. (B) LPS and various concentrations of the H2 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H2 modulates TNF-α release. Data is presented 
as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H2 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v and stimulates at 1 x 10-6 % w/v 
(see 2.35A - 1 x 10-4 56.3 ± 2.6, 1 x 10-6 113.0 ± 1.9). H2 fraction of F2 inhibits cytokine TNF-α 
release at 1 x 10-4 % w/v and stimulates at 1 x 10-6 % w/v, 1 x 10-8 % w/v and 1 x 10-10 % w/v (see 
2.35B - 1 x 10-4 68.3 ± 5.4, 1 x 10-6 139.7 ± 5.8, 1 x 10-8 120.0 ± 12.9, 1 x 10-10 116.7 ± 4.0).  
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Figure 2.36 – H3 fraction of F2 stimulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H3 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H3 stimulates IL-1β release. (B) LPS and various concentrations of the H3 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H2 stimulates TNF-α release. Data is presented 
as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H3 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v, 1 x 10-6 % w/v and 1 x 10-8 % w/v 
(see 2.36A - 1 x 10-4 113.5 ± 3.4, 1 x 10-6 114.7 ± 4.3, 1 x 10-8 110.5 ± 5.4). H3 fraction of F2 
stimulates cytokine TNF-α release in all concentrations (see 2.36B - 1 x 10-4 156.0 ± 3.3, 1 x 10-6 
160.7 ± 4.7, 1 x 10-8 152.2 ± 7.5, 1 x 10-10 115.7 ± 3.9).  
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Figure 2.37 – H4 fraction of F2 stimulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H4 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H4 stimulates IL-1β release. (B) LPS and various concentrations of the H4 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H4 stimulates TNF-α release. Data is presented 
as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H4 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v, 1 x 10-6 % w/v and 1 x 10-8 % w/v 
(see 2.37A - 1 x 10-4 117.3 ± 5.3, 1 x 10-6 113.3 ± 3.2, 1 x 10-8 112.8 ± 3.6). H4 fraction of F2 
stimulates cytokine TNF-α release in all concentrations (see 2.37B - 1 x 10-4 162.2 ± 4.6, 1 x 10-6 
139.0 ± 6.0, 1 x 10-8 160.5 ± 5.1, 1 x 10-10 120.3 ± 6.0).  
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Figure 2.38 – H5 fraction of F2 stimulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H5 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H5 modulates IL-1β release. (B) LPS and various concentrations of the H5 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H5 stimulates TNF-α release. Data is presented 
as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H5 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v and stimulates at 1 x 10-8 % w/v 
(see 2.38A - 1 x 10-4 61.7 ± 3.1, 1 x 10-8 119.7 ± 4.4). H5 fraction of F2 stimulates cytokine TNF-α 
release at concentrations of 1 x 10-6 % w/v and 1 x 10-8 % w/v (see 2.38B - 1 x 10-6 130.3 ± 15.8, 1 
x 10-8 151.3 ± 10.8).  
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Figure 2.39 – H6 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H6 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H6 modulates IL-1β release. (B) LPS and various concentrations of the H6 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H6 modulates TNF-α release. Data is presented 
as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H6 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v and stimulates release at 1 x 10-6 
% w/v and 1 x 10-8 % w/v (see 2.39A - 1 x 10-4 20.2 ± 6.5, 1 x 10-6 116.5 ± 3.9, 1 x 10-8 113.7 ± 
3.8). H6 fraction of F2 stimulates cytokine TNF-α release at 1 x 10-4 % w/v and stimulates release 
at 1 x 10-6 % w/v and 1 x 10-8 % w/v (see 2.39B - 1 x 10-4 57.5 ± 4.3, 1 x 10-6 148.2 ± 2.4, 1 x 10-8 
149.5 ± 2.3).  
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Figure 2.40 – H7 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H7 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H7 inhibits IL-1β release. (B) LPS and various concentrations of the H7 fraction of F2 
were added to PMA-differentiated THP-1 cells. H7 does not modulate TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H7 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v (see 2.40A - 1 x 10-4 85.0 ± 5.8). 
H7 fraction of F2 does not modulate cytokine TNF-α release (see 2.40B).  
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Figure 2.41 – H8 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H8 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H8 inhibits IL-1β release. (B) LPS and various concentrations of the H8 fraction of F2 
were added to PMA-differentiated THP-1 cells. H8 modulates TNF-α release. Data is presented as 
mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H8 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v and 1 x 10-6 % w/v (see 2.41A - 1 
x 10-4 38.2 ± 2.3, 1 x 10-6 81.8 ± 2.4). H8 fraction of F2 inhibits cytokine TNF-α release at 1 x 10-4 
% w/v and stimulates at 1 x 10-6 % w/v and 1 x 10-8 % w/v (see 2.41B - 1 x 10-4 19.3 ± 3.3, 1 x 10-6 
117.2 ± 3.2, 1 x 10-8 126.0 ± 2.8).  
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Figure 2.42 – H9 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H9 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H9 inhibits IL-1β release. (B) LPS and various concentrations of the H9 fraction of F2 
were added to PMA-differentiated THP-1 cells. H9 modulates TNF-α release. Data is presented as 
mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H9 fraction of F2 inhibits cytokine IL-1β release at concentrations of 1 x 10-4 % w/v and 1 x 10-6 % 
w/v (see 2.42A - 1 x 10-4 38.2 ± 2.3, 1 x 10-6 88.0 ± 3.3). H9 fraction of F2 inhibits cytokine TNF-α  
at a concentration of 1 x 10-4 % w/v and stimulates at 1 x 10-8 % w/v (see 2.42B - 1 x 10-4 20.7 ± 
1.9, 1 x 10-8 149.2 ± 3.2).  
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Figure 2.43 – H10 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H10 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H10 modulates IL-1β release. (B) LPS and various concentrations of the H10 fraction 
of F2 were added to PMA-differentiated THP-1 cells. H10 stimulates TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H10 fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v and 
stimulates at 1 x 10-6 % w/v (see 2.43A - 1 x 10-4 76.0 ± 2.5, 1 x 10-6 115.8 ± 5.8). H10 fraction of 
F2 stimulates cytokine TNF-α release in all concentrations (see 2.43B - 1 x 10-4 143.2 ± 5.7, 1 x 10-
6 149.3 ± 5.3, 1 x 10-8 161.8 ± 8.4, 1 x 10-10 126.0 ± 6.8).  
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Figure 2.44 – H11 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H11 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H11 inhibits IL-1β release. (B) LPS and various concentrations of the H11 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H11 modulates TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H11 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v and 1 x 10-6 % w/v (see 2.44A - 
1 x 10-4 113.5 ± 3.4, 1 x 10-6 114.7 ± 4.3). H11 fraction of F2 inhibits cytokine TNF-α release at a 
concentration of 1 x 10-4 % w/v and stimulates at 1 x 10-6 % w/v and 1 x 10-10 % w/v (see 2.44B - 1 
x 10-4 156.0 ± 3.3, 1 x 10-6 160.7 ± 4.7, 1 x 10-10 115.7 ± 3.9).  
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Figure 2.45 – H12 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H12 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H12 inhibits IL-1β release. (B) LPS and various concentrations of the H12 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H12 modulates TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H12 fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v and 1 x 10-6 
% w/v (see 2.45A - 1 x 10-4 76.0 ± 2.5, 1 x 10-6 87.6 ± 1.6). H12 fraction of F2 inhibits cytokine 
TNF-α release at a concentration of 1 x 10-4 % w/v and stimulates at 1 x 10-6 % w/v, 1 x 10-8 % w/v 
and 1 x 10-10 % w/v.  (see 2.45B - 1 x 10-4 24.5 ± 3.5, 1 x 10-6 132.8 ± 6.2, 1 x 10-8 139.7 ± 3.9, 1 x 
10-10 115.8 ± 6.2).  
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Figure 2.46 – H13 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H13 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H13 inhibits IL-1β release. (B) LPS and various concentrations of the H13 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H13 does not modulate TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H13 fraction of F2 inhibits cytokine IL-1β release at 1 x 10-4 % w/v (see 2.46A - 1 x 10-4 70.0 ± 0.8). 
H13 fraction of F2 does not modulate cytokine TNF-α release (see 2.46B).  
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Figure 2.47 – H14 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H14 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H14 inhibits IL-1β release. (B) LPS and various concentrations of the H14 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H14 stimulates TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H14 fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v (see 2.47A - 
1 x 10-4 88.2 ± 1.5). H14 fraction of F2 stimulates cytokine TNF-α release at concentrations of 1 x 
10-4 % w/v and 1 x 10-6 % w/v (see 2.47B - 1 x 10-4 116.7 ± 2.9, 1 x 10-6 119.2 ± 1.9).  
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Figure 2.48 – H15 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H15 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H15 inhibits IL-1β release. (B) LPS and various concentrations of the H15 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H15 does not modulate TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H15 fraction of F2 inhibits cytokine IL-1β release at concentrations of 1 x 10-4 % w/v and 1 x 10-6 % 
w/v (see 2.48A - 1 x 10-4 113.5 ± 3.4, 1 x 10-6 114.7 ± 4.3). H15 fraction of F2 does not modulate 
cytokine TNF-α release (see 2.48B).  
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Figure 2.49 – H16 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H16 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H15 inhibits IL-1β release. (B) LPS and various concentrations of the H16 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H16 stimulates TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H16 fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v (see 2.49A - 
1 x 10-4 84.3 ± 1.8). H16 fraction of F2 stimulates cytokine TNF-α release at a concentration of  1 x 
10-6 % w/v (see 2.49B - 1 x 10-6 118.8 ± 2.8).  
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Figure 2.50 – H17 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H17 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H17 does not modulate IL-1β release. (B) LPS and various concentrations of the H17 
fraction of F2 were added to PMA-differentiated THP-1 cells. H17 modulates TNF-α release. Data 
is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H17 fraction of F2 does not modulate cytokine IL-1β release (see figure 2.50A). H17 fraction of F2 
inhibits cytokine TNF-α release at a concentration of 1 x 10-4 % w/v and stimulates at 1 x 10-8 % 
w/v (see figure 2.50B - 1 x 10-4 72.8 ± 3.6, 1 x 10-8 122.5 ± 5.7).  
  
 140 
 
 
A 
 
 
 
B 
 
 
  
DM
SO
 
LP
S C
on
tro
l 
H1
8 [
10
-4 ]
H1
8 [
10
-6 ]
H1
8 [
10
-8 ]
H1
8 [
10
-10
]
0
50
100
150
H18 fraction of F2 inhibits
 IL-1β release
Treatment (%)
IL
-1
β
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗
DM
SO
 C
on
tro
l
LP
S C
on
tro
l 
H1
8 [
10
-4 ]
H1
8 [
10
-6 ]
H1
8 [
10
-8 ]
H1
8 [
10
-10
]
0
50
100
150
H18 fraction of F2 modulates
 TNF-α release
Treatment (%)
TN
F-
α
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗
∗ ∗
 141 
Figure 2.51 – H18 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H18 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H18 inhibits IL-1β release. (B) LPS and various concentrations of the H18 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H18 modulates TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H18 fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v (see figure 
2.51A - 1 x 10-4 76.0 ± 2.5). H18 fraction of F2 inhibits cytokine TNF-α release at a concentration of 
1 x 10-4 % w/v and stimulates at 1 x 10-6 % w/v and 1 x 10-8 % w/v (see figure 2.51B - 1 x 10-4 24.5 
± 3.5, 1 x 10-6 117.5 ± 4.1, 1 x 10-8 124.2 ± 3.6).  
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Figure 2.52 – H19 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H19 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H19 inhibits IL-1β release. (B) LPS and various concentrations of the H19 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H19 stimulates TNF-α release. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H19 fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v (see figure 
2.52A - 1 x 10-4 67.2 ± 1.2). H19 fraction of F2 stimulates cytokine TNF-α release at concentrations 
of 1 x 10-6 % w/v and 1 x 10-8 % w/v (see figure 2.52B - 1 x 10-6 122.8 ± 9.9, 1 x 10-8 124.0 ± 4.9).  
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Figure 2.53 – H20 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H20 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H20 does not modulate IL-1β release. (B) LPS and various concentrations of the H20 
fraction of F2 were added to PMA-differentiated THP-1 cells. H20 stimulates TNF-α release. Data 
is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H20 fraction of F2 does not modulate cytokine IL-1β release (see figure 2.53A). H20 fraction of F2 
stimulates cytokine TNF-α release at concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v (see 
figure 2.53B - 1 x 10-4 125.5 ± 7.2, 1 x 10-6 115.0 ± 2.4).  
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Figure 2.54 – H21 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H21 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H21 modulates IL-1β release. (B) LPS and various concentrations of the H21 fraction 
of F2 were added to PMA-differentiated THP-1 cells. H21 does not modulate TNF-α release. Data 
is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H21 fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v and 
stimulates at 1 x 10-8 % w/v (see figure 2.54A - 1 x 10-4 58.7 ± 2.9, 1 x 10-8 113.2 ± 3.8). H21 
fraction of F2 does not modulate cytokine TNF-α release (see figure 2.54B).  
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Figure 2.55 – H22 fraction of F2 inhibits cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H22 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H22 inhibits IL-1β release. (B) LPS and various concentrations of the H22 fraction of 
F2 were added to PMA-differentiated THP-1 cells. H22 inhibits TNF-α release. Data is presented 
as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H22 fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v (see figure 
2.55A - 1 x 10-4 31.7 ± 5.7). H22 fraction of F2 inhibits cytokine TNF-α release at a concentration of 
1 x 10-4 % w/v (see figure 2.55B - 1 x 10-4 48.7 ± 3.3).  
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Figure 2.56 – H23 fraction of F2 does not modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the H23 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H23 does not modulate IL-1β release. (B) LPS and various concentrations of the H23 
fraction of F2 were added to PMA-differentiated THP-1 cells. H23 does not modulate TNF-α 
release. Data is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H23 fraction of F2 does not modulate cytokine IL-1β release (see figure 2.56A). H23 fraction of F2 
does not modulate cytokine TNF-α release (see figure 2.56B).  
  
 152 
 
 
A 
 
 
 
B 
 
 
  
DM
SO
 
LP
S C
on
tro
l 
H2
4 [
10
-4 ]
H2
4 [
10
-6 ]
H2
4 [
10
-8 ]
H2
4 [
10
-10
]
0
50
100
150
H24 fraction of F2 does not
modulate IL-1β release
Treatment (%)
IL
-1
β
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
DM
SO
 C
on
tro
l
LP
S C
on
tro
l 
H2
4 [
10
-4 ]
H2
4 [
10
-6 ]
H2
4 [
10
-8 ]
H2
4 [
10
-10
]
0
50
100
150
H24 fraction of F2 does not
modulate TNF-α release
Treatment (%)
TN
F-
α
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
 153 
Figure 2.57 – H24 fraction of F2 does not modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the H24 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H24 does not modulate IL-1β release. (B) LPS and various concentrations of the H24 
fraction of F2 were added to PMA-differentiated THP-1 cells. H24 does not modulate TNF-α 
release. Data is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H24 fraction of F2 does not modulate cytokine IL-1β release (see figure 2.57A). H24 fraction of F2 
does not modulate cytokine TNF-α release (see figure 2.57B).  
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Figure 2.58 – H25 fraction of F2 does not modulate cytokine IL-1β and TNF-α expression in 
PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the H25 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H25 does not modulate IL-1β release. (B) LPS and various concentrations of the H25 
fraction of F2 were added to PMA-differentiated THP-1 cells. H25 does not modulate TNF-α 
release. Data is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H25 fraction of F2 does not modulate cytokine IL-1β release (see figure 2.58A). H25 fraction of F2 
does not modulate cytokine TNF-α release (see figure 2.58B).  
  
 156 
 
 
A 
 
 
 
B 
 
 
  
DM
SO
 
LP
S C
on
tro
l 
H2
6 [
10
-4 ]
H2
6 [
10
-6 ]
H2
6 [
10
-8 ]
H2
6 [
10
-10
]
0
50
100
150
H26 fraction of F2 does not
modulate IL-1β release
Treatment (%)
IL
-1
β
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
DM
SO
 C
on
tro
l
LP
S C
on
tro
l 
H2
6 [
10
-4 ]
H2
6 [
10
-6 ]
H2
6 [
10
-8 ]
H2
6 [
10
-10
]
0
50
100
150
H26 fraction of F2 stimulates
 TNF-α release
Treatment (%)
TN
F-
α
 re
le
as
e 
no
rm
al
is
ed
 (%
)
p<0.05 vs LPS∗
∗
 157 
Figure 2.59 – H26 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H26 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H26 does not modulate IL-1β release. (B) LPS and various concentrations of the H26 
fraction of F2 were added to PMA-differentiated THP-1 cells. H26 stimulates TNF-α release. Data 
is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H26 fraction of F2 does not modulate cytokine IL-1β release (see figure 2.59A). H26 fraction of F2 
stimulates cytokine TNF-α release at a concentration of 1 x 10-4 % w/v (see figure 2.59B - 1 x 10-4 
127.5 ± 10.6).  
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Figure 2.60 – H27 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H27 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H27 does not modulate IL-1β release. (B) LPS and various concentrations of the H27 
fraction of F2 were added to PMA-differentiated THP-1 cells. H27 stimulates TNF-α release. Data 
is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H27 fraction of F2 does not modulate cytokine IL-1β release (see figure 2.60A). H27 fraction of F2 
stimulates cytokine TNF-α release at a concentration of 1 x 10-4 % w/v (see figure 2.60B - 1 x 10-4 
121.5 ± 9.7).  
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Figure 2.61 – H28 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H28 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H28 does not modulate IL-1β release. (B) LPS and various concentrations of the H28 
fraction of F2 were added to PMA-differentiated THP-1 cells. H28 stimulates TNF-α release. Data 
is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H28 fraction of F2 does not modulate cytokine IL-1β (see figure 2.61A). H28 fraction of F2 
stimulates cytokine TNF-α release at a concentration of 1 x 10-4 % w/v (see figure 2.61B - 1 x 10-4 
146.0 ± 6.2).  
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Figure 2.62 – H29 fraction of F2 modulates cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H29 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H29 does not modulate IL-1β release. (B) LPS and various concentrations of the H29 
fraction of F2 were added to PMA-differentiated THP-1 cells. H29 stimulates TNF-α release. Data 
is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H29 fraction of F2 does not modulate cytokine IL-1β release (see figure 2.62A). H29 fraction of F2 
stimulates cytokine TNF-α release at concentrations of 1 x 10-4 % w/v , 1 x 10-6 % w/v and 1 x 10-8 
% w/v (see figure 2.62B - 1 x 10-4 135.5 ± 3.6, 1 x 10-6 123.0 ± 3.5, 1 x 10-8 145.0 ± 8.0).  
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Figure 2.63 – Load fraction of F2 inhibits cytokine IL-1β and TNF-α expression in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the load fraction of F2 were added to PMA-differentiated 
THP-1 cells. The load fraction inhibits IL-1β release. (B) LPS and various concentrations of the 
load fraction of F2 were added to PMA-differentiated THP-1 cells. The load fraction inhibits TNF-α 
release. Data is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
Load fraction of F2 inhibits cytokine IL-1β release at a concentration of 1 x 10-4 % w/v and 1 x 10-6 
% w/v (see 2.63A - 1 x 10-4 52.0 ± 12.0, 1 x 10-6 84.8 ± 6.1). Load fraction of F2 inhibits cytokine 
TNF-α release at a concentration of 1 x 10-4 % w/v (see 2.63B - 1 x 10-4 68.2 ± 11.5).  
 
 
2.5 Discussion 
Up regulation of cytokines IL-1β and TNF-α is usually associated with inflammatory conditions and 
therefore stimulation of these is intuitively counterproductive in drug discovery for anti inflammatory 
agents. However, up regulation of pro-inflammatory cytokines by biological extracts may have a 
role in the treatment of malignancies. Shark cartilage, a well known alternative medicine has been 
shown to reduce angiogenesis in tumour formation81 while also increasing release of TNF-α and IL-
1β82. While the fractions for this thesis were chosen based primarily on their anti-inflammatory 
properties this does not exclude the potential for pro-inflammatory fractions for other medical uses 
such as cancer research. All first generation fractions with the exception of the chosen fraction 44E 
had activity that resulted in the increase in the release of cytokines TNF-α and IL-1β. Second 
generation fractions did not display global increase in both cytokines however third generation 
fractions H3, H4, H5 and H10 increased both TNF-α and IL-1β. (See figure 2.64) 
 
Biological extracts such as Uncaria tomentoa is an biological extract that inhibits TNF-α release 
while stimulating IL-1β in a LPS-stimulated in-vitro model83. This study points to MAP kinase 
pathway inhibition by the extract as its primary mechanism of action.  First generation fractions 
44W, 44E, 45W share this trait along with second generation fractions F6, F7, F19 and F22. Not 
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surprisingly as third generation fractions were born from F2, which does not share this trait, they do 
not inhibit TNF-α while stimulating IL-1β release. (See figure 2.64) 
 
Biological extracts have been shown to significantly inhibit cytokine IL-1β. Ziziphus jujuba84 and 
Illicium verum85 are among two of these extracts that significantly inhibits IL-1β though this list is 
extremely long. Biological extracts that inhibit many pro-inflammatory cytokines are of particular 
interest for their potential use as anti-inflammatory agents. Biophytum sensitivum, a traditional 
medicinal extract does inhibit IL-1β, TNF-α as well as other pro-inflammatory cytokines COX-2 and 
IL-686. Ficus religiosa similarly causes inhibiting of pro-inflammatory cytokines87. Of all first 
generation fractions there was only one that significantly inhibited both cytokines tested; 44E was 
therefore chosen as the candidate for further fractionation. Second generation fractions that 
inhibited cytokines tested included F2, F4, F9, F10 and F17. Of these fractions F2, F4 and F10 all 
inhibited NF-κB translocation concurrently. F2 selection as the primary candidate was based on 
overall concentration-based inhibition throughout all parameters measured (IL-1β, TNF-α release 
and NF-κB translocation). Third generation fractions that inhibit both cytokines include H2, H6, H9, 
H11, H12, H18 and H22 though only H22 inhibited both without some concurrent stimulation of IL-
1β or TNF-α release. (See figure 2.64). 
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 IL-1β TNF-α 
 Inhibitors Stimulators Inhibitors Stimulators 
First Generation 44E 44W, 45W, 45E, 
46W, 46E, 47W, 
47E 
44E, 45W 44W, 45E, 46E, 
47W, 47E 
Second Generation F2, F4, F9, 
F10, F13, F17 
F6, F7, F18, 
F19, F21, F22 
F2, F3, F4, F5, 
F6, F7, F8, F9, 
F10, F12, F17, 
F19, F20, F22 
F1, F13, F15 
Third Generation H7, H8, H9, 
H14, H15, 
H16, H18, 
H19, H22 
H2, H3, H4, H5, 
H6, H10, H11, 
H12, H13, H21 
H22 H2, H3, H4, H5, 
H6, H8, H9, H10, 
H11, H12, H14, 
H16, H17, H18, 
H19, H20, H26, 
H27, H28, H29 
 
Figure 2.64 – Summary of results for the release of inflammatory cytokines TNF-α and IL-1β 
in the three generations of fractions. 
 
 
2.6 Conclusions 
Final generation fractions that significantly modulate cytokines TNF-α and IL-1β may have potential 
applications in treating chronic inflammatory conditions or as novel anti-cancer agents. Mechanistic 
insight into the activity of these extracts may be somewhat clarified by the addition of their effect on 
the translocation of NF-κB and cell viability via the MTT assay.  
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Chapter 3 
Activity-guided investigation of the bioactivity of Ecobiotics™ bioactive 
extracts using immunofluorescence to quantify NF-κB translocation in 
LPS-stimulated, PMA-differentiated human monocytes. 
 
 
3.1 Foreword 
This chapter will outline the specific role of the NF-ĸB pathway in inflammation and why modulators 
of this pathway are novel therapeutic targets. Biological extract fractions are screened using 
quantitative immunofluorescence to assess NF-ĸB translocation in human monocytes for the 
purpose of activity-guided fractionation. Extracts that modulate the translocation of NF-ĸB will be 
discussed as potential therapeutic targets. 
 
3.2 Introduction 
Translocation of NF-κB and other signal transduction pathways such as phosphoinositide 3-kinase 
(PI3K) and are often used for high content screening as they allow for fast identification of cellular 
effect88. As outlined in chapter 1.3.4 the NF-κB pathway is thought to, when activated, allow 
transcription of many pro-inflammatory mediators. The translocation of NF-κB is a vital step in this 
cascade and a focus of high-content screening for this reason.  
 
The hallmark of the activation of the NF-κB pathway is the translocation of this transcription factor 
from the cytosol to the nucleus of the cell. When labelled with immunoflorescent antibodies this 
process can be quantified using a process called automated high-content screening microscopy. 
High-content refers in this case to the multiple data points (in this case multiple wavelengths) that 
can be analysed simultaneously. Along with quantifying florescence intensity this technology can 
quantify its subcellular location and morphology making it particularly useful in determining 
translocation from the cytosol to the nucleus89. 
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Previous, semi-quantitative methods for determining whether NF-κB translocation had occurred 
involved an electrophoretic gel-shift assay. This assay uses large cultures of the initial cells and 
allows them to bind to labelled nucleotide sequences (32P-labelled) specific for the proteins in 
question. Once bound the sample is placed within a polyacrylamide gel and electrophoresed. The 
un-bound deoxyribose nucleic acid (DNA) moves through the gel faster than the bound creating 
bands of isotope-labelled, bound DNA. This method is relatively expensive and time consuming 
when compared to modern high content screening, time consuming and requires the use of 
radioisotopes90. 
 
In order to guide the fractionation and purification of biological extracts high-content screening 
microscopy was used to quantify the translocation of NF-κB in PMA-differentiated THP-1 cells.  
 
3.3 Materials and Methods 
3.3.1 Culturing THP-1 cells and differentiation 
The culture and differentiation of THP-1 cells in described in chapter 2, sections 2.3.1. For these 
experiments a cells/well density of 150,000 were seeded into 96 well plates then incubated at 37°C 
in humidified 5% C02 for 48 hours. At 48 hours the media was carefully replaced with fresh 
complete media containing RPMI 1640 with 10% foetal bovine serum (FBS) and 1% 
Penicillin/Streptomycin and further incubated for 24 hours. Serum starving of the cells occurred by 
replacing the media with RMPI 1640 supplemented with 2% FBS and further incubating for 12 
hours before treatment occurred. 
 
3.3.2 Preparation of samples 
Four initial crude extracts deemed active in modulating IL-1β and NF-κB by Phan et al13 were 
kindly provided by Ecobiotics™ and fractionated by QIMR laboratories on behalf of the author. 
These fractions were dried and weighed following the first fractionation, which allowed accurate 
reconstitution in sterile DMSO alone. Second and third generation extracts were in too small 
volumes to accurately weigh so the dried fractions were reconstituted in the same amount of sterile 
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DMSO across all fractions of a generation to allow comparison. The amount of DMSO used for the 
initial dilution was estimated to give the same weight/volume dilutions across all fractions.  
 
3.3.3 Treating differentiated THP-1 cells 
The serum-starved and PMA-differentiated THP-1 cells are treated with a media solution 
containing RMPI 1640 with 10% FBS. Control wells contain the media and DMSO alone while the 
treatment wells and positive control wells contain lipopolysaccharide (LPS) isolated and purified 
from Escherichia coli at a concentration of 0.1µg/mL (Enzo Life Sciences, New York, USA). This 
concentration of LPS was previously optimised for use in this assay. Treatments were performed in 
triplicate wells at 100µL/well and all experimental plates were designed to contain positive and 
negative controls as well as selected treatments for continuity. Following treatment plates were 
incubated at 37°C in humidified 5% C02 for one hour. 
 
3.3.4 Fluorescent immunohistochemistry 
Following treatment and incubation for one hour the treatment solution was removed carefully from 
the plates and then washed in triplicate with 100µL/well of phosphate-buffered saline (PBS) (for 
composition of PBS see appendix 1.1). Cells were fixed with 3.7% formaldehyde in PBS for 15 
minutes at room temperature before being washed in triplicate with PBS again. Blocking buffer 
(see appendix 1.2) was added to each well at 50µL/well and plates were left to incubate for one 
hour. 
Blocking buffer is removed and rabbit anti-NF-κB p65 [E739] primary antibody is added at 
30uL/well (p65 prepared as per appendix 1.3; Abcam, Cambridge, UK) before undergoing 
incubation overnight at 4°C with humidification. Once removed, cells were washed in triplicate with 
PBS before being incubated for 2 hours with 30uL/well of goat anti-rabbit secondary antibody (see 
appendix 1.4; Abcam, Cambridge, UK) under low-light conditions. Remaining solution is removed 
at 2 hours and further washing in triplicate with PBS takes place before a final incubation for 10 
minutes with 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI)  at 30uL/well takes place (see 
appendix 1.5; Sapphire Biosciences, Redfern, NSW, Australia). Finally cells were washed in 
triplicate with PBS before viewing under the imaging microscope. 
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3.3.5 Quantitative fluorescent imaging analysis 
Images from the cells were captured by the ImageXpress, an automated epifluorescent 
microscope, using a 10x objective. Four different fields of view were obtained from each well 
(897.84 x 670.80 µm). For Cy3/NF-κB the excitation occurred at 553 nm and emission at 568 nm 
while for DAPI the excitation occurred at 345 nm and the emission at 455 nm. Captured data was 
analysed quantitatively for NF-κB translocation using software MetaXpress® a product of 
Molecular Devices Corperation, Downington, PA, USA. 
 
3.3.6 Data analysis 
All data is presented as mean ± standard error of mean (SEM) unless otherwise stated. Statistical 
significance was determined with one-way analysis of variance (ANOVA) with p<0.05. Post hoc 
testing was carried out using Dunnet’s test to compare treatments against control (LPS and media 
alone) group. 
 
3.4 Results 
3.4.1 First generation fractions of biological extracts inhibit NF-ĸB translocation in PMA-
differentiated THP-1 cells 
Active biological extracts screened previously91 were fractionated into either ethyl acetate or water 
soluble fractions (see section 1.5.5.1) and these were named as per figure 2.1. Four initial 
fractions, each with water and ethyl acetate fractions were assessed for their ability to inhibit the 
NF-ĸB translocation in PMA-differentiated THP-1 cells. The first generation fractions that 
significantly inhibited NF-ĸB were 44E, 45W, 45E, 46E, 47W and 47E. 
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Figure 3.1 - Water and ethyl acetate-soluble fractions of extract 44 modulate NF-ĸB 
translocation in PMA-differentiated THP-1 cells 
(A) LPS and a range of concentrations of the water-soluble fraction of extract 44 (44W) were 
added to PMA-differentiated THP-1 cells. 44W does not modulate NF-ĸB translocation. (B) LPS 
and various concentrations of the ethyl acetate-soluble fraction of extract 44 (44E) were added to 
PMA-differentiated THP-1 cells. 44E inhibits NF-ĸB translocation. Data is presented as mean ± 
SEM where n = 3 (represents 3 independent experiments). 
 
While 44W did not modulate NF-ĸB translocation (see figure 3.1A) 44E was able to significantly 
inhibit NF-ĸB as low as 1 x 10-10 % w/v with higher concentrations of the extract providing 
significantly more inhibition (see figure 3.1B - 1 x 10-4 43.5 ± 5.6, 1 x 10-6 72.8 ± 5.1, 1 x 10-8 84.31 
± 6.2 and 1 x 10-8 83.39 ± 6.2).  
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Figure 3.2 - Water and ethyl acetate-soluble fractions of extract 45 modulate NF-ĸB 
translocation in PMA-differentiated THP-1 cells 
(A) LPS and a range of concentrations of the water-soluble fraction of extract 45 (45W) were 
added to PMA-differentiated THP-1 cells. 45W inhibits NF-ĸB translocation. (B) LPS and various 
concentrations of the ethyl acetate-soluble fraction of extract 45 (45E) were added to PMA-
differentiated THP-1 cells. 45E inhibits NF-ĸB translocation. Data is presented as mean ± SEM 
where n = 3 (represents 3 independent experiments). 
 
45W inhibited NF-ĸB translocation in a non-concentration dependant mechanism at concentrations 
of 1 x 10-6% w/v and 1 x 10-10% w/v though not 1 x 10-4% w/v and 1 x 10-8% w/v (see figure 3.2A - 
1 x 10-6 66.6 ± 6.6, 1 x 10-10 71.5 ± 7.1). 45E inhibited NF-ĸB translocation in all concentrations 
tested (see figure 3.2B - 1 x 10-4 64.6 ± 5.6, 1 x 10-6 67.6 ± 8.4, 1 x 10-8 74.9 ± 7.4, 1 x 10-10 65.1 ± 
6.7). 
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Figure 3.3 - Water and ethyl acetate-soluble fractions of extract 46 modulate NF-ĸB 
translocation in PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the water-soluble fraction of extract 46 (46W) were added to 
PMA-differentiated THP-1 cells. 46W does not modulate NF-ĸB translocation. (B) LPS and various 
concentrations of the ethyl acetate-soluble fraction of extract 46 (46E) were added to PMA-
differentiated THP-1 cells. 46E inhibits NF-ĸB translocation. Data is presented as mean ± SEM 
where n = 3 (represents 3 independent experiments). 
 
 
46W does not modulate NF-ĸB translocation (see figure 3.3A). 46E inhibited NF-ĸB translocation in 
concentrations of  1 x 10-4% w/v and 1 x 10-6% w/v only (see figure 3.3B - 1 x 10-4 79.7 ± 2.1, 1 x 
10-6 77.3 ± 3.5). 
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Figure 3.4 - Water and ethyl acetate-soluble fractions of extract 47 modulate NF-ĸB 
translocation in PMA-differentiated THP-1 cells 
(A) LPS and various concentrations of the water-soluble fraction of extract 47 (47W) were added to 
PMA-differentiated THP-1 cells. 47W inhibits NF-ĸB translocation. (B) LPS and various 
concentrations of the ethyl acetate-soluble fraction of extract 47 (47E) were added to PMA-
differentiated THP-1 cells. 47E inhibits NF-ĸB translocation. Data is presented as mean ± SEM 
where n = 3 (represents 3 independent experiments). 
 
47W inhibited NF-ĸB translocation in a non-dose dependant mechanism at concentrations of 1 x 
10-6% w/v and 1 x 10-10% w/v though not 1 x 10-4% w/v and 1 x 10-8% w/v (see figure 3.4A - 1 x 10-
6 74.4 ± 3.9, 1 x 10-10 77.2 ± 4.6). 47E inhibited NF-ĸB translocation in all concentrations (see figure 
3.4B - 1 x 10-4 78.8 ± 3.6, 1 x 10-6 60.9 ± 5.1, 1 x 10-8 78.9 ± 2.6, 1 x 10-10 53.7± 5.7)  
 
3.4.2 Second-generation fractions of 44E modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
Outlined in chapter 2 is the process of fractionating the selected ethyl acetate-soluble fraction of 
extract 44 which was shown to be significantly inhibitory for the release of cytokines TNF–α and IL-
1β (see chapter 2) as well as inhibiting translocation of NF-κB. This fractionation process revealed 
22 second-generation fractions, which were prepared as per section 1.5.5.2 (see figure 2.10) and 
underwent testing for modulation of NF-κB translocation in PMA-differentiated THP-1 cells. The 
results of these second generation fractions are reported below along with the load; which 
represents the unfractionated sample.  
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Figure 3.5 - F1 and F2 fractions of 44E modulate NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of F1 fraction of 44E were added to PMA-differentiated THP-1 
cells. F1 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of the F2 
fraction of 44E were added to PMA-differentiated THP-1 cells. F2 inhibits NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F1 did not significantly modulate NF-ĸB translocation (see figure 3.5A). F2 inhibited NF-ĸB 
translocation in higher concentrations; 1 x 10-4% w/v, 1 x 10-6% w/v and 1 x 10-8% w/v respectively 
(see figure 3.5B - 1 x 10-4 48.58 ± 4.6, 1 x 10-6 58.2 ± 4.4, 1 x 10-8 67.9 ± 4.4)  
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Figure 3.6 – F3 and F4 fractions of 44E modulate NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of the F3 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F3 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of the 
F4 fraction of 44E were added to PMA-differentiated THP-1 cells. F4 inhibits NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F3 did not significantly modulate NF-ĸB translocation (see figure 3.6A). F4 inhibited NF-ĸB 
translocation significantly in two higher concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v only 
(see figure 3.6B - 1 x 10-4 77.5 ± 4.9, 1 x 10-6 77.8 ± 5.7).   
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Figure 3.7 – F5 and F6 fractions of 44E do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F5 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F5 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of the 
F6 fraction of 44E were added to PMA-differentiated THP-1 cells. F6 does not modulate NF-ĸB 
translocation. Data is presented as mean ± SEM where n = 3 (represents 3 independent 
experiments). 
 
Both F5 and F5 did not significantly modulate NF-ĸB translocation (see figures 3.7A and 3.7B 
respectively).  
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Figure 3.8 – F7 and F8 fractions of 44E do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
A) LPS and various concentrations of the F7 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F7 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of the 
F8 fraction of 44E were added to PMA-differentiated THP-1 cells. F8 does not modulate NF-ĸB 
translocation. Data is presented as mean ± SEM where n = 3 (represents 3 independent 
experiments). 
 
Both F7 and F8 did not significantly modulate NF-ĸB translocation (see figures 3.8A and 3.8B 
respectively).  
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Figure 3.9 – F9 and F10 fractions of 44E modulate NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of the F9 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F9 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of the 
F10 fraction of 44E were added to PMA-differentiated THP-1 cells. F10 inhibits NF-ĸB 
translocation. Data is presented as mean ± SEM where n = 3 (represents 3 independent 
experiments). 
 
F9 did not significantly modulate NF-ĸB translocation (see figure 3.9A). F10 inhibited NF-ĸB 
translocation significantly in one concentration of 1 x 10-6 % w/v only (see figure 3.9B - 1 x 10-6 
94.75 ± 2.4) 
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Figure 3.10 – F11 and F12 fractions of 44E inhibit NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of the F11 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F11 inhibits NF-ĸB translocation. (B) LPS and various concentrations of the F12 
fraction of 44E were added to PMA-differentiated THP-1 cells. F12 inhibits NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F11 inhibited NF-ĸB translocation significantly in one concentration of 1 x 10-6 % w/v (see figure 
3.10A - 1 x 10-6 73.6 ± 2.9). F12 inhibited NF-ĸB translocation significantly in one concentration of 
1 x 10-6 % w/v (see figure 3.10B - 1 x 10-6 76.4 ± 2.2). 
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Figure 3.11 – F13 and F14 fractions of 44E do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the 13 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F13 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the F14 fraction of 44E were added to PMA-differentiated THP-1 cells. F14 does not modulate NF-
ĸB translocation. Data is presented as mean ± SEM where n = 3 (represents 3 independent 
experiments). 
 
Both F13 and F14 did not significantly modulate NF-ĸB translocation (see figures 3.11A and 3.11B 
respectively).   
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Figure 3.12 – F15 and F16 fractions of 44E do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F15 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F15 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the F16 fraction of 44E were added to PMA-differentiated THP-1 cells. F16 does not modulate NF-
ĸB translocation. Data is presented as mean ± SEM where n = 3 (represents 3 independent 
experiments). 
 
Both F15 and F16 did not significantly modulate NF-ĸB translocation (see figures 3.12A and 3.12B 
respectively).   
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Figure 3.13 – F17 and F18 fractions of 44E stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F17 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F17 stimulates NF-ĸB translocation. (B) LPS and various concentrations of the F18 
fraction of 44E were added to PMA-differentiated THP-1 cells. F18 stimulates NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F17 significantly stimulates NF-ĸB translocation in all concentrations (see figure 3.13A - 1 x 10-4 
127.8 ± 4.6, 1 x 10-6 134.6 ± 5.1, 1 x 10-8 133.9 ± 4.9, 1 x 10-10 124.2± 6.5). F18 significantly 
stimulates NF-κB translocation in all concentrations (see figure 3.13B - 1 x 10-4 149.2 ± 4.6, 1 x 10-
6 135.6 ± 5.3, 1 x 10-8 146.4 ± 6.8, 1 x 10-10 134.1± 8.8)   
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Figure 3.14 – F19 and F20 fractions of 44E stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F19 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F19 stimulates NF-ĸB translocation. (B) LPS and various concentrations of the F20 
fraction of 44E were added to PMA-differentiated THP-1 cells. F20 stimulates NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 3 (represents 3 independent experiments). 
 
F19 significantly stimulated NF-ĸB translocation in all concentrations (see figure 3.14A - 1 x 10-4 
157.3 ± 4.4, 1 x 10-6 124.6 ± 6.2, 1 x 10-8 146.4± 5.9, 1 x 10-10 132.8 ± 4.4). F20 significantly 
stimulated NF-ĸB translocation significantly in two concentrations of 1 x 10-4 % w/v and 1 x 10-8 % 
w/v respectively (see figure 3.14B - 1 x 10-4 150.3 ± 4.4, 1 x 10-8 131.5 ± 5.1)   
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Figure 3.15 – F21 and F22 fractions of 44E stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the F21 fraction of 44E were added to PMA-differentiated 
THP-1 cells. F21 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the F22 fraction of 44E were added to PMA-differentiated THP-1 cells. F22 stimulates NF-ĸB 
translocation. Data is presented as mean ± SEM where n = 3 (represents 3 independent 
experiments). 
 
F21 does not modulate NF-ĸB translocation (see figure 3.15A). F22 stimulates NF-ĸB translocation 
significantly at a concentration of 1 x 10-4 % w/v only (see figure 3.15B - 1 x 10-4 119.3 ± 4.1)   
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Figure 3.16 – Load fraction of 44E inhibits NF-ĸB translocation in PMA-differentiated THP-1 
cells 
(A) LPS and various concentrations of the load fraction of 44E were added to PMA-differentiated 
THP-1 cells. The load fraction of 44E inhibits NF-ĸB translocation. Data is presented as mean ± 
SEM where n = 3 (represents 3 independent experiments). 
 
The load fraction inhibits NF-ĸB translocation in a concentration of 1 x 10-4 % w/v only (see figure 
3.16A - 1 x 10-4 64.5 ± 3.6).  
 
 
3.4.3 Third generation fractions of biological extracts modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
Outlined in section 1.5.5.3 is the process of fractionating the selected second-generation fraction of 
F2. F2 was shown to significantly reduce the release of cytokines TNF–α and IL-1β (see chapter 2 
figure 2.11) as well as inhibiting translocation of NF-κB (see figure 3.5B).  
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Fractionation using the HPLC reverse phase method for F2 using a methanol and water solvent 
mix yielded 29 sub-fractions (third generation fractions) which are named H1 through to H29. 
These fractions become more hydrophilic as the number increases (see section 1.5.5.3). 29 
fractions plus a load fraction that represents an unfractionated sample underwent testing for 
modulation of NF-κB translocation in PMA-differentiated THP-1 cells. The results of H1 to H29 
fractions and the load are reported below. 
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Figure 3.17 – H1 and H2 fractions of F2 inhibit NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of the H1 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H1 inhibits NF-ĸB translocation. (B) LPS and various concentrations of the H2 fraction 
of F2 were added to PMA-differentiated THP-1 cells. H2 inhibits NF-ĸB translocation. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H1 inhibits NF-ĸB translocation at 1 x 10-4 % w/v only (see figure 3.17A - 1 x 10-6 63.8 ± 11.7). H2 
inhibits NF-ĸB translocation significantly in the two higher concentrations of 1 x 10-4 % w/v and 1 x 
10-6 % w/v (see figure 3.17B - 1 x 10-4 30.3 ± 7.4, 1 x 10-6 49.5 ± 8.1)  
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Figure 3.18 – H3 and H4 fractions of F2 inhibit NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of the H3 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H3 inhibits NF-ĸB translocation. (B) LPS and various concentrations of the H4 fraction 
of F2 were added to PMA-differentiated THP-1 cells. H4 inhibits NF-ĸB translocation. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H3 inhibits NF-ĸB translocation at 1 x 10-4 % w/v only (see figure 3.18A - 1 x 10-4 69.6± 12.5). H2 
does not significantly modulate NF-ĸB translocation (see figure 3.18B).  
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Figure 3.19 – H5 and H6 fractions of F2 inhibit NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of the H5 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H5 inhibits NF-ĸB translocation. (B) LPS and various concentrations of the H6 fraction 
of F2 were added to PMA-differentiated THP-1 cells. H6 inhibits NF-ĸB translocation. Data is 
presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H5 inhibits NF-ĸB translocation at 1 x 10-4 % w/v only (see figure 3.19A - 1 x 10-4 65.0 ± 8.3). H6 
inhibits NF-ĸB translocation at 1 x 10-4 % w/v only (see figure 3.19B - 1 x 10-4 60.6± 15.3). 
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Figure 3.20 – H7 and H8 fractions of F2 modulate NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of the H7 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H7 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of the 
H8 fraction of F2 were added to PMA-differentiated THP-1 cells. H8 inhibits NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 1 (represents 1 independent experiment). 
 
H7 does not modulate NF-ĸB translocation (see figure 3.20A). H8 inhibits NF-ĸB translocation 
significantly in one concentration of 1 x 10-4 % w/v only (see figure 3.20B - 1 x 10-4 83.6 ± 2.6)  
  
 212 
 
A 
 
 
B 
 
 
  
DM
SO
 
LP
S C
on
tro
l 
H9
 [1
0-
4 ]
H9
 [1
0-
6 ]
H9
 [1
0-
8 ]
H9
 [1
0-
10 ]
0
50
100
150
H9 fraction of F2 does not
modulate NF-κB translocation
Treatment (%)
N
or
m
al
is
ed
 N
F-
κ
B
 tr
an
sl
oc
at
io
n 
(%
)
p<0.05 vs LPS∗
DM
SO
 
LP
S C
on
tro
l 
H1
0 [
10
-4 ]
H1
0 [
10
-6 ]
H1
0 [
10
-8 ]
H1
0 [
10
-10
]
0
50
100
150
H10 fraction of F2 does not
modulate NF-κB translocation
Treatment (%)
N
or
m
al
is
ed
 N
F-
κ
B
 tr
an
sl
oc
at
io
n 
(%
)
p<0.05 vs LPS∗
 213 
Figure 3.21 – H9 and H10 fractions of F2 do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H9 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H9 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of the 
H10 fraction of F2 were added to PMA-differentiated THP-1 cells. H10 does not modulate NF-ĸB 
translocation. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiment). 
 
Both H9 and H10 do not modulate NF-ĸB translocation (see figures 3.21A and 3.21B).   
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Figure 3.22 – H11 and H12 fractions of F2 inhibit NF-ĸB translocation in PMA-differentiated 
THP-1 cells 
(A) LPS and various concentrations of the H11 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H11 inhibits NF-ĸB translocation. (B) LPS and various concentrations of the H12 
fraction of F2 were added to PMA-differentiated THP-1 cells. H12 inhibits NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 1 (represents 1 independent experiments). 
 
H11 significantly inhibits NF-ĸB translocation at 1 x 10-4 % w/v only (see figure 3.22A - 1 x 10-4 48.0 
± 6.9). H12 significantly inhibits NF-ĸB translocation significantly at 1 x 10-4 % w/v only (see figure 
3.22B - 1 x 10-4 41.1 ± 6.6)   
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Figure 3.23 – H13 and H14 fractions of F2 do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H13 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H13 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the H14 fraction of F2 were added to PMA-differentiated THP-1 cells. H14 does not modulate NF-
ĸB translocation. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
Both H13 and H14 do not modulate NF-ĸB translocation (see figures 3.23A and 3.23B). 
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Figure 3.24 – H15 and H16 fractions of F2 do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H15 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H15 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the H16 fraction of F2 were added to PMA-differentiated THP-1 cells. H16 does not modulate NF-
ĸB translocation. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
Both H15 and H16 do not modulate NF-ĸB translocation (see figures 3.24A and 3.24B). 
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Figure 3.25 – H17 and H18 fractions of F2 modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H17 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H17 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the H18 fraction of F2 were added to PMA-differentiated THP-1 cells. H18 inhibits NF-ĸB 
translocation. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
F17 does not modulate NF-ĸB translocation (see figure 3.25A). H18 significantly inhibits NF-ĸB 
translocation in the highest concentration of 1 x 10-4 % w/v (see figure 3.25B - 1 x 10-4 75.7 ± 13.2) 
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Figure 3.26 – H19 and H20 fractions of F2 stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H19 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H19 stimulates NF-ĸB translocation. (B) LPS and various concentrations of the H20 
fraction of F2 were added to PMA-differentiated THP-1 cells. H20 stimulates NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 1 (represents 1 independent experiments). 
 
H19 significantly stimulates NF-ĸB translocation at 1 x 10-6 % w/v (see figure 3.26B - 1 x 10-4 138.4 
± 7.2). H20 significantly stimulates NF-ĸB translocation at 1 x 10-4 % w/v, 1 x 10-6 % w/v and 1 x 10-
8 % w/v (see figure 3.26B - 1 x 10-4 140.3 ± 13.2, 1 x 10-6 131.8 ± 5.3, 1 x 10-8 129.2 ± 7.6). 
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Figure 3.27 – H21 and H22 fractions of F2 stimulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H21 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H21 stimulates NF-ĸB translocation. (B) LPS and various concentrations of the H22 
fraction of F2 were added to PMA-differentiated THP-1 cells. F22 stimulates NF-ĸB translocation. 
Data is presented as mean ± SEM where n = 1 (represents 1 independent experiments). 
 
F21 significantly stimulates NF-ĸB translocation in concentrations of 1 x 10-4 % w/v, 1 x 10-6 % w/v 
and 1 x 10-8 % w/v (see figure 3.27A - 1 x 10-4 158.2 ± 11.7, 1 x 10-6 149.6 ± 6.9 and 1 x 10-6 138.3 
± 13.1). F22 significantly stimulates NF-ĸB translocation in concentrations of 1 x 10-4 % w/v and 1 x 
10-8 % w/v (see figure 3.27B - 1 x 10-4 132.7 ± 13.2 and 1 x 10-6 147.8 ± 7.4).  
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Figure 3.28 – H23 and H24 fractions of F2 modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H23 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H23 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the H24 fraction of F2 were added to PMA-differentiated THP-1 cells. H24 inhibits NF-ĸB 
translocation. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
Both H23 dos not modulate NF-ĸB translocation (see figure 3.28A) H24 significantly inhibits NF-ĸB 
translocation concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v (see figure 3.28B - 1 x 10-4 110.8 
± 8.6 and 1 x 10-6 106.8 ± 10.8).  
 228 
 
A 
 
 
B 
 
 
  
DM
SO
 
LP
S C
on
tro
l 
H2
5 [
10
-4 ]
H2
5 [
10
-6 ]
H2
5 [
10
-8 ]
H2
5 [
10
-10
]
0
50
100
150
H25 fraction of F2 does not
modulate NF-κB translocation
Treatment (%)
N
or
m
al
is
ed
 N
F-
κ
B
 tr
an
sl
oc
at
io
n 
(%
)
p<0.05 vs LPS∗
DM
SO
 
LP
S C
on
tro
l 
H2
6 [
10
-4 ]
H2
6 [
10
-6 ]
H2
6 [
10
-8 ]
H2
6 [
10
-10
]
0
50
100
150
H26 fraction of F2 does not
modulate NF-κB translocation
Treatment (%)
N
or
m
al
is
ed
 N
F-
κ
B
 tr
an
sl
oc
at
io
n 
(%
)
p<0.05 vs LPS∗
 229 
Figure 3.29 – H25 and H26 fractions of F2 do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H25 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H25 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the H26 fraction of F2 were added to PMA-differentiated THP-1 cells. H26 does not modulate NF-
ĸB translocation. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
Both H25 and H26 do not modulate NF-ĸB (see figures 3.29A and 3.29B respectively).   
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Figure 3.30 – H27 and H28 fractions of F2 do not modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H27 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H27 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the H28 fraction of F2 were added to PMA-differentiated THP-1 cells. H28 does not modulate NF-
ĸB translocation. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
Both H27 and H28 do not modulate NF-ĸB (see figures 3.30A and 3.30B respectively).  
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Figure 3.31 – H29 and load fractions of F2 modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
(A) LPS and various concentrations of the H29 fraction of F2 were added to PMA-differentiated 
THP-1 cells. H29 does not modulate NF-ĸB translocation. (B) LPS and various concentrations of 
the load fraction of F2 were added to PMA-differentiated THP-1 cells. The load fraction inhibits NF-
ĸB translocation. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
H29 does not modulate NF-ĸB translocation (see figure 3.31A). The load fraction significantly 
inhibits NF-ĸB translocation in concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v (see figure 
3.31B - 1 x 10-4 48.8 ± 4.6 and 1 x 10-6 62.2 ± 6.4)  
 
 
3.5 Discussion 
The role of NF-κB in inflammatory pathways and specifically in CRS has been outlined previously 
in chapter 1. Its role as a pro-inflammatory mediator makes it an ideal target for novel anti-
inflammatory agents. The results in this chapter are used, in conjunction with the results from 
chapter 3, to guide the purification of biological extracts in the hope of locating a novel therapeutic 
agent capable of inhibiting this pathway. 
 
Biological extracts have been shown in the literature to significantly modulate the translocation of 
NF-κB both inhibiting it and promoting it. Chandrasekhar et al discovered while investigating the 
biological activity of curcumin, an extract from turmeric that NF-κB translocation and subsequent 
gene expression was significantly inhibited by it92. A similar response has been noted with 
tocotrienols, the active component of vitamin E93, resveratriol from grapeseed94, crocetin from 
saffron39 and carotenoid from yellow fruits and vegetables such as carrot95.  
 
Activation of the NF-κB pathway involves promotion of translocation. Initially this activation is 
thought to be pro-inflammatory though recent research indicates that activation of this pathway, 
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namely through activation of the IKKα subunit of the IKB kinase heterodimer which controls NF-κB 
activation. It is thought that activation of IKKα may accelerate the degredation of NF-κB subunits 
effectively halting the macrophage activation and inflammation96. Activators of NF-κB may 
therefore become essential for ceasing chronic inflammatory states and are worthy of investigation 
in the same manor as inhibitors of NF-κB. 
 
3.5.1 First generation fractions of biological extracts modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
First generation fractions of four active Ecobiotics™ extracts were screened for their modulation of 
NF-κB translocation in PMA-differentiated THP-1 cells. Overall the results in section 3.4.1 indicate 
that these fractions tend towards inhibiting the translocation of NF-κB. More specifically, fractions 
45W (1 x 10-6 % w/v, 1 x 10-10 % w/v), 45E (all concentrations), 46E (1 x 10-4 % w/v, 1 x 10-6 % 
w/v), 47W (1 x 10-6 % w/v, 1 x 10-10 % w/v) and 47E (all concentrations), all had some inhibitory 
activity on NF-κB translocation in these experiments. Not surprisingly the more active fractions 
were the fractions more readily dissolved in ethyl acetate (organic fractions) rather than water as is 
often the case in activity-guided fractionation72. 
 
When comparing these first generation fractions alone 45E or 47E might indicate the most 
powerful inhibition of NF-κB translocation however when the cytokine inhibition of both IL-1β and 
TNF-α is taken into account (see section 2) the fraction with the most overall inhibition of pro-
inflammatory markers in PMA-differentiated THP-1 cells is 44E. (See figure 3.32) 
 
3.5.2 Second-generation fractions of 44E modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
Outlined in chapter 2 is the process of liquid-phase chromatography in which 44E was fractionated 
into 22 separate fractions based on their relative solubility in three liquid solvents; methanol, 
ethanol and ethyl acetate, each becoming more hydrophilic respectively. These 22 fractions along 
with a load fraction, which represents an unfractionated sample of 44E, were tested for their 
modulation of NF-κB translocation.  
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The majority of fractions indicated no significant modulation to NF-κB translocation with the 
exception of F2, which inhibited NF-κB down to a concentration of 1 x 10-8 % w/v. Fractions F4, 
F10 and F11 all had some inhibition at a middle concentration of 1 x 10-6 % w/v. The significance 
of this inhibition is likely to be relatively small when compared to the dose-dependant inhibition of 
fraction F2. A number of fractions stimulated the translocation of NF-κB; F17 (1 x 10-4 % w/v, 1 x 
10-8 % w/v, 1 x 10-10 % w/v), F18 (all concentrations), F19 (1 x 10-4 % w/v, 1 x 10-8 % w/v, 1 x 10-10 
% w/v), F20 (1 x 10-4 % w/v, 1 x 10-8 % w/v), F21 (1 x 10-8 % w/v) and F22 (all concentrations). 
Finally the unfractionated sample was consistent with the findings from section 3.4.1 with inhibition 
occurring in higher concentrations of 1 x 10-4 % w/v, 1 x 10-6 % indicating the repeatability of the 
experimental control.  
 
F2 was the only fraction with a dose-dependant inhibition of NF-κB translocation and this activity 
was subsequently seen in the reduction of cytokines IL-1β and TNF-α in chapter 2. As a result of 
this fraction was further fractionated as outlined in chapter 2 to further purify and isolate this active 
component and potential anti-inflammatory therapeutic target. (See figure 3.32) 
 
3.5.3 Third generation fractions of biological extracts modulate NF-ĸB translocation in PMA-
differentiated THP-1 cells 
Chapter 2 outlines the process of the creation of the third-generation of fractions; fractions of F2. A 
high-performance liquid chromatography (HPLC) was used over a water-methanol gradient to 
extract 29 fractions of F2 based on relative solubility in methanol and water. These 29 fractions 
along with a load fraction, which represents an unfractionated sample of F2, were tested for their 
modulation of NF-κB translocation.  
 
Significant modulation to NF-κB translocation was seen in five of the 29 fractions of F2 along with 
the load fraction, acting as the experimental control. H2 (1 x 10-4 % w/v), H8 (1 x 10-4 % w/v), H12 
(1 x 10-4 % w/v) and H18 (1 x 10-4 % w/v) all inhibited NF-κB translocation in higher concentrations.  
H21 stimulated NF-κB translocation in concentrations of 1 x 10-4 % w/v and 1 x 10-6 % w/v in a 
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does-dependant manor. The load fraction showed dose-dependant inhibition of NF-κB 
translocation confirming the experimental control.  
 
Of the fractions of F2 that showed some activity of inhibition towards NF-κB H2 was the only 
fraction with a dose-dependant inhibition of NF-κB translocation and this activity was subsequently 
seen in the reduction of cytokines IL-1β and TNF-α in chapter 3 in higher concentrations tested. 
(See figure 3.32) 
 
 NF-κB 
 Inhibitors Stimulators 
First Generation 44E, 45W, 45E, 46E, 47W, 47E  
Second Generation F2, F4, F10, F11, F12 F17, F18, F19, F20, F22 
Third Generation H1, H2, H3, H5, H6, H8, H24 H11, H12, H18, H19, H20, 
H21, H22 
 
Figure 3.32 – Summary of results for the translocation of NF-κB in three generations of 
fractions. 
 
3.6 Conclusions 
From originally screened activity of crude extracts by Phan et al73, active extracts underwent 
activity-guided fractionation in three generations identifying potential fractions that sustained 
inhibition of NF-κB translocation. The third generation of fractions revealed four possible fractions 
(H2, H8, H12, H18) with inhibition of NF-κB translocation that will be further discussed in chapter 6 
with regards to their effect on cell viability (chapter 5) and overall potential as a therapeutic anti-
inflammatory targets. 
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Chapter 4  
Effect of fractionated biological extracts on cell viability in PMA-
differentiated THP-1 Cells 
 
4.1 Foreword 
Extracts and fractions that modulate cytokines and nuclear factors need to be assessed for toxicity 
to the system that screened them. Cell viability assays use enzymatic reduction of tetrazolium salts 
to achieve this and give a good estimation of relative affect on cell viability in a system.      
          
4.2 Introduction 
While drug discovery focuses on bioactivity of a possible therapeutic on a cellular system there are 
limitations of these bioactivity assays that may give false positive results such as cell necrosis or 
apoptosis. Cell viability assays use the properties of healthy cells to create a quantitative 
measurement of viability. These can be a simple as a trypan blue dye exclusion assay which uses 
the ability of a healthy cell to exclude the trypan blue dye to assess, and count, viable cells97.  
 
The introduction of high-throughput screening required the use of adherent cells and the metabolic 
activity of these cells could be detected by a metabolic dye. The dye is inactive and introduced into 
the system before it’s reduced by the enzymes within a healthy cell. The active dye can then be 
quantified by use of light-spectrum absorbance. Common dyes used are 3-(4,5-dimethythiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium)-
bis-(4-methoxy-6-nitro) benzene sulphonic acid hydrate) (XTT) and (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2- (4-sulphophenyl)-2H-tetrazolium) (MTS)97. Newer dyes such as XTT 
and MTS may be more sensitive in some systems though their use is limited to particular cells 
types97. 
 
MTT is perhaps the most widely used tetrazolium reduction assay due to its robustness and ease 
of use97. MTT is a yellow powder that undergoes reduction primarily in the cytoplasm of cells to a 
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blue-coloured formazan. The reduction requires extracellular glucose to power nucleotide cofactors 
and as such exhausted culture medium may provide falsely low reduction of MTT97. Formazan 
crystals must then be solublised in a solvent such as DMSO to allow absorbance readings.  
 
4.3 Materials and Methods 
4.3.1 Culturing THP-1 cells and differentiation 
THP-1 cells are cultured and differentiated as described in chapter 2.3.1. For the purpose of this 
assay cells were brought to approximately 90% confluency and seeded onto 24 well plates at 
500,000 cells/well. The plates were then incubated at 37°C, 5% humidified CO2 for 48 hours. 
 
4.3.2 Preparing samples 
Samples were prepared as described in 2.3.2 
 
4.3.3 Treating differentiated THP-1 cells 
Once incubated cells were treated with extracts in various concentrations along with media 
containing RPMI 1640 with 10% FBS and 1% Penicillin/streptomycin. Treatment volume was 500 
µL/well with all plates designed to have both controls along with treatments to allow normalisation. 
Treatment was carried out over 24 hours in the incubator at 37°C, 5% humidified CO2. 
 
4.3.4 MTT tetrazolium reduction assay 
The Thiazolyl Blue Tetrazolium Bromide Cels Reduction Assay™ or MTT assay is used to 
determine cell viability. Preperation of the MTT reagent solution requires the dilution of the 
tetrazolium salt into media containing RPMI 1640 with 10% FBS and 1% penicillin/streptomycin. 
This salt/media solution is sterile filtered through a 0.22 µm syringe-top filter (Millipore, North Ryde, 
NSW, Australia). When not in use the solution was maintained at -20°C in low light conditions. For 
use the solution was diluted to 2.5 mg/mL and warmed. 
 
Treatment media was aspirated after 24 hours and 220 µL of the diluted tetrazolium reagent 
mixture was added to each well and incubated for 4 hours at 37°C, 5% humidified CO2. The 
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reagent mixture is then aspirate and replaced with DMSO and incubated at room temperature, in 
low light, with slow shaking for 20 minutes. DMSO volume was adjusted to 100 µL/well and 
transferred to a 96 well clear plate. 
 
4.3.5 Absorbance  
96 well plate was read for absorbances by a Bio-Rad 550 microplate reader at 595 nm. 
 
4.3.6 Data analysis 
Data was analysed and presented as mean ± SEM with significance as determined by ANOVA 
(p<0.05) with Bonferroni used for post-hoc analysis. 
 
4.4 Results 
8 third generation fractions were considered potential therapeutic targets due to their modulation of 
cytokines IL-1β and TNF-α and modulation of NF-κB translocation in THP-1 cells. Cell viability was 
assessed below. 
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4.4.1 Cell viability assay of third generation fractions of biological extracts 
 
 
Figure 4.1 – H2 does not affect cell viability in differentiated THP-1 cells 
LPS and various concentrations of H2 fraction of F2 (from 44E) were added to PMA-differentiated 
THP-1 cells and assessed for enzymatic reduction of a tetrazolium dye. H2 fraction does not 
significantly affect cell viability. Data is presented as mean ± SEM where n = 1 (represents 1 
independent experiments). 
 
H2 fraction of F2 (from 44E) does not significantly modulate formazan concentration and 
absorbance in treated media compared to media alone (see figure 4.1).  
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Figure 4.2 – H6 does not affect cell viability in differentiated THP-1 cells 
LPS and various concentrations of H6 fraction of F2 (from 44E) were added to PMA-differentiated 
THP-1 cells and assessed for enzymatic reduction of a tetrazolium dye. H6 fraction does not 
significantly affect cell viability. Data is presented as mean ± SEM where n = 1 (represents 1 
independent experiments). 
 
H6 fraction of F2 (from 44E) does not significantly modulate formazan concentration in treated 
media compared to media alone (see figure 4.2).  
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Figure 4.3 – H8 affects cell viability in differentiated THP-1 cells 
LPS and various concentrations of H8 fraction of F2 (from 44E) were added to PMA-differentiated 
THP-1 cells and assessed for enzymatic reduction of a tetrazolium dye. H8 fraction significantly 
affects cell viability. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
H8 fraction of F2 (from 44E) significantly modulates formazan concentration in treated media 
compared to media alone. At higher concentrations of 1 x 10-4 % w/v cell viability is reduced 
though at lower concentrations of 1 x 10-8 % w/v it increases (see figure 4.3 - 1 x 10-4 79.1 ± 3.3, 1 
x 10-8  119.9 ± 5.9).  
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Figure 4.4 – H9 affects cell viability in differentiated THP-1 cells 
LPS and various concentrations of H9 fraction of F2 (from 44E) were added to PMA-differentiated 
THP-1 cells and assessed for enzymatic reduction of a tetrazolium dye. H9 fraction significantly 
reduced cell viability. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
H9 fraction of F2 (from 44E) significantly reduced formazan concentration in treated media 
compared to media alone. At higher concentrations of 1 x 10-4 % w/v cell viability is reduced to 
(see figure 4.4 -1 x 10-4 78.9 ± 3.3).  
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Figure 4.5 – H11 affects cell viability in differentiated THP-1 cells 
LPS and various concentrations of H11 fraction of F2 (from 44E) were added to PMA-differentiated 
THP-1 cells and assessed for enzymatic reduction of a tetrazolium dye. H11 fraction significantly 
affected cell viability. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
H11 fraction of F2 (from 44E) significantly reduced formazan concentration in treated media 
compared to media alone. At a high concentration of 1 x 10-4 % w/v cell viability is reduced while at 
a low concentrations of 1 x 10-6 and 1 x 10-8 % w/v it increases it (see figure 4.5 - 1 x 10-4 79.6 ± 
3.4, 1 x 10-6 125.3 ± 8.2, 1 x 10-8 128.8 ± 7.9).  
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Figure 4.6 – H12 affects cell viability in differentiated THP-1 cells 
LPS and various concentrations of H12 fraction of F2 (from 44E) were added to PMA-differentiated 
THP-1 cells and assessed for enzymatic reduction of a tetrazolium dye. H12 fraction significantly 
affected cell viability. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
H12 fraction of F2 (from 44E) significantly affected formazan concentration in treated media 
compared to media alone. At a high concentration of 1 x 10-4 % w/v cell viability is reduced while at 
a low concentrations of 1 x 10-6 and 1 x 10-8 % w/v it increases (see figure 4.6 - 1 x 10-4 66.1 ± 2.9, 
1 x 10-6 124.1 ± 9.6, 1 x 10-8 127.3 ± 6.7).  
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Figure 4.7 – H18 affects cell viability in differentiated THP-1 cells 
LPS and various concentrations of H18 fraction of F2 (from 44E) were added to PMA-differentiated 
THP-1 cells and assessed for enzymatic reduction of a tetrazolium dye. H18 fraction significantly 
affected cell viability. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
H18 fraction of F2 (from 44E) significantly affected formazan concentration in treated media 
compared to media alone. At a high concentration of 1 x 10-4 % w/v cell viability is reduced while at 
a low concentrations of 1 x 10-6 and 1 x 10-8 % w/v it increases (see figure 4.7 - 1 x 10-4 74.3 ± 3.6, 
1 x 10-6 129.8 ± 8.2, 1 x 10-8 119.8 ± 8.3).  
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Figure 4.8 – H22 affects cell viability in differentiated THP-1 cells 
LPS and various concentrations of H22 fraction of F2 (from 44E) were added to PMA-differentiated 
THP-1 cells and assessed for enzymatic reduction of a tetrazolium dye. H22 fraction did not affect 
cell viability. Data is presented as mean ± SEM where n = 1 (represents 1 independent 
experiments). 
 
H22 fraction of F2 (from 44E) did not significantly affect formazan concentration in treated media 
compared to media alone (see figure 4.8).  
 
 
4.5 Discussion 
 
Analysing the data acquired from the MTT assay requires a clear understanding of the purpose for 
its use (cell viability verses screening for example) and the potential properties of the treatments. A 
reduction in the absorbance may indicate an unfavourable toxicity in one system while being a 
favourable result as to a potential for investigation in anti cancer research98. H2, H6 and H22 
fractions did not affect the production of formazan crystals in PMA-differentiated THP-1 cells in any 
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concentration (See figure 4.9). In this experiment MTT is used as a surrogate for mitochondrial 
function and overall cell viability as it has been used in plant-based extracts for this purpose 
before99-101 thus it can be inferred that these fractions do not affect basic mitochondrial functioning 
of this cellular system and are not harmful or toxic to it.  Subsequently fractions that stimulate and 
inhibit formazan crystal formation at various concentrations may represent either mixtures of active 
compounds or may be directly affecting the reduction of the MTT dye itself101. 
 
 
 MTT Cell Viability 
 Reduce viability No effect (or stimulate) 
Third Generation H9 H2, H6, H8, H11, H12, H18 
H22 
 
Figure 4.9 – Summary of results for the third generation fractions undergoing the MTT cell 
viability assay. 
 
 
Biological extracts have shown concentration-dependant modulation of cell proliferation in the 
literature. Curcumin for example inhibits TNF-α release in lower concentrations (10 nM) while 
arresting cell proliferation as determined by an MTT assay in higher concentration of 100 nM in 
mouse macrophages102. Saskatoon berry and quercetin were shown to inhibit TNF-α in the same 
mouse model while causing proliferation of cells as determined by the MTT assay102 indicating 
multiple pathways may be activated or inhibited by these extracts. Similiarly fractions H8, H9, H11, 
H12 and H18 all cause inhibition of the MTT assay at higher concentrations indicating a reduced 
mitochondrial function which likely represents toxicity. (See Figure 4.9) 
 
A study by Cavallini et al103 investigated salicylates and other NF-κB inhibitors and found that the 
cell proliferation was inhibited by compounds that inhibited NF-κB suggesting a link between NF-κB 
translocation and cell proliferation. This may explain why fractions H8, H9, H11, H12 and H18 all 
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showed inhibition of NF-κB in higher concentrations coupled with reduced cell viability as 
determined by the MTT assay.  
 
The MTT cell viability assay does have limitations such as exhausted culture media giving false-
low results as discussed in section 4.2. One limitation specific to biological extracts is the ability for 
some naturally occurring anti-oxidants to reduce MTT providing false-high results101. Resveratrol, 
N-acetylcysteine and Vitamin E are among the reducers of MTT101 as well as curcumin and 
quercetin to name a few99. This reducing power of some natural antioxidants has lead to the use of 
the MTT to screen for this property among natural extracts99. It may be that fractions H8, H11, H12 
and H18, which all cause some elevation in absorbance in the MTT, are in fact direct reducers of 
the MTT or antioxidants. Subsequently induction of mitochondrial function as is the case in cell 
proliferation may also explain this. 
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Chapter 5  
Discussion and Conclusions 
 
 
CRS is a disease of particular importance in drug discovery due to its health burden and lack of 
effective and low-risk therapies. The inflammatory pathways and cytokines up regulated in CRS 
are similar to those seen in inflammatory conditions such as inflammatory bowel disease and 
rheumatoid arthritis104,105, as such, novel therapeutics that modulate these inflammatory pathways 
are of interest to the wider medical community. 
 
Biological extracts have been studied with respect to inflammatory pathway modulation with many 
studies progressing past in vitro experimental models such as resveritrol for treating 
artherosclerosis in mice106 or grapeseed for treating asthma in mice107. The differential modulation 
of these inflammatory pathways by extracts and their ease of collection make them ideal targets for 
high-throughput screening and purification. 
 
Using a generic model of inflammation such as THP-1 cells for high-throughput screening allows 
the findings to be extrapolated further than one disease process, while being specific enough to 
allow direct correlation of potential therapeutic findings to CRS108,109. Subsequently THP-1 cells are 
commonly used in cancer research evaluating similar pathways including NF-κB and cytokines 
TNF-α and IL-1β making the findings of screening potential therapeutics in this model widely 
applicable110. 
 
This research has chosen to investigate the activity of fractions of natural Australian botanicals 
sourced from Ecobiotics™ through modulation of cytokines IL-1β, TNF-α and NF-κB translocation 
and hence guide the purification of these fractions. Fractions that inhibited the release of these 
cytokines and inhibited NF-κB were thought to have potential as therapeutic agents in treating 
CRS. One first generation fraction displayed these properties; 44E and subsequently underwent 
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fractionation via silica gel column chromatography. Three second generation fractions also 
displayed this inhibitory activity and the one with the greatest inhibitory activity was chosen for 
further fractionation by means of HPLC. Of this final generation three fractions named H2, H6 and 
H22 all showed promising inhibitory activity while not affecting cell viability as determined by the 
MTT cell viability assay. These three fractions are deemed near-pure compounds by the 
specialised drug-discovery lab that performed the fractionation. For a profile on the HPLC 
fractionation please refer to appendix 7.5. Although some of the third generation of fractions were 
deemed near-pure compounds it is likely that the majority of this final generation contain multiple 
individual compounds. 
 
Ethyl acetate fractions of crude extracts commonly have within them organically active compounds 
such as polyphenols and tannins and are commonly selected over the extracts of more polar 
solvents such as water for further fractionation in similar drug-discovery models111-113. This does 
not hold true as a rule as water-soluble fractions can also contain active molecules such as an in 
vitro antihyperglycaemic investigated by Matsui et al114. The search for an anti inflammatory in this 
thesis lead to the fractionation of the ethyl acetate portion of the crude organic extract due to 44E 
being the only first generation fraction with global anti inflammatory property against cytokines IL-
1β, TNF-α and signal transduction protein NF-κB. There was pro-inflammatory bioactivity of the 
remainder of fractions, both water and ethyl acetate, which may represent toxicity to the cell 
system or genuine bioactivity against these pathways. The only way to discriminate in this case 
would be to follow each of these fractions along their own path of fractionation and study their 
cellular toxicity as was performed on 44E.  
 
The fractions of these crude extracts proved to be considerably active throughout the generations. 
When using bioactivity-guided extracts of botanical sources this is not uncommon. Heyman et al 
showed 22 of 64 extracts of Helichrysum populifolium showed activity against the human 
immunodeficiency virus (HIV) in their in vitro model78, roughly 30%. The final HPLC fractionation 
separation may be limited by the solvents used in the mobile phase; specifically by their viscocity 
and polarisability which in turn may be affected by the temperature of the column or the purity of 
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the solvent115. Poor separation of a HPLC column may give many active fractions all containing 
similar or the same compounds or multiple bioactivities may be due to many different bioactive 
compounds present. The differentiation would arise when further analysis is made with NMR or 
mass spectrometry. 
 
Possible contaminations in the fractions may include previous solvents, from poorly dried fractions; 
light contamination, if active ingredients are light sensitive and finally contamination by endotoxins 
which may influence the results of the experiments. The most serious of these contaminations are 
endotoxins (such as LPS) which do exist within botanical extracts116. These endotoxins, if present, 
can modulate the inflammatory pathways similar to LPS. They can be filtered from the extracts 
using a process such as endotoxin-specific polymyxin B-conjugated affinity column116 and detected 
as contaminants using an endotoxin detection assay such as a limulus amebocyte lysate assay117. 
Although the extracts used in this thesis were sterile filtered and maintained in sterile, low-light 
conditions throughout the research, not testing for endotoxin contamination remains an unlikely, 
though serious limitation to these results. 
 
Biological impurities present in the third generation can be, for the majority, deduced by the 
process of concurrent spectrometry and NMR/IR absorbance’s118. Whether these are inert or 
potentially active will determine if further HPLC would be required to purify these or simply if this 
compound can be synthesised then the impurity(s) are not an issue once the bioactivity is 
confirmed. 
 
Current topical therapies for CRS including mometasone furoate and fluticasone propionate have 
been shown to reduce cytokines IL-2, IL-17, INF-γ and TNF-α in an ex vivo model of CRS119. In 
vitro studies similarly show mometasone to be more effective than dexamethasone at decreasing 
levels of IL-1β, IL-6 and TNF-α120. Biological extracts such as G. robusta, S. nigra, A. montana, 
and Q. amara have also been shown to significantly reduce level of pro-inflammatory cytokines IL-
1β, TNF-α, nitric oxide and IL-12 in vitro121. It follows that biological extracts modulating the release 
of one, or many of these pro-inflammatory pathways may serve as a novel therapeutic for the 
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treatment of CRS. Final generation fractions H2, H6 and H22 are all potential therapeutics under 
this banner. In order to compare this data to known anti-inflammatory treatments such as 
dexamethasone the work of Nga et al used identical experimental design and tested the effects of 
dexamethasone in this model at various concentrations. The roughly 50% normalised reduction of 
IL-1β and TNF-α cytokine by H2, H6 and H22 at weight per volume concentration of 1 x 10-4 wv 
compares to the same activity around 1 x 10-7 w/v of dexamethasone73. This corresponds to a 
much weaker anti-inflammatory activity. Similarly with NF-κB the highest reduction in translocation 
by the third generation fractions at 1 x 10-4 w/v corresponds to a concentration of dexamethasone 
of 1 x 10-8 w/v. 
 
Therapeutic agents that inhibit the NF-κB pathway may do so directly by inhibiting the translocation 
of NF-κB and downstream gene transcription of pro-inflammatory cytokines such as MOL-294, 
dexamethasone or the extract of Houttuynia cordata which block the production of NF-κB 
dependant cytokine production independently104,122. Current therapeutic agents used to treat CRS 
topically include mometasone furoate and fluticasone propionate; both corticosteroids. Their use 
has been shown to similarly reduce NF-κB transcriptional effects in vitro123. Along with these known 
treatments for CRS, biological extracts that inhibit NF-κB such as third generation extracts H2 and 
H6 may show therapeutic promise. 
 
Models of inflammation, such as LPS-stimulated, PMA-differentiated THP-1 cells, used in high-
throughput screening provide a relatively cheap, repeatable and reliable insight into potential 
bioactivity. When screening for novel therapeutic agents for a particular disease process however 
models such as these do have significant limitations. Monocellular culture cannot demonstrate the 
interactions between cell types that exist in a complex diseased tissue124. Screening through 
multiple cell type monocultures seen in a particular disease process could in part mitigate this. 
Screening crude extracts or complex mixtures of biological extracts may lead to negative results 
due to interactions between compounds themselves. This can be mitigated by fractionation though 
this process is more time consuming and carries more expense125. Finally screening biological 
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extracts based on activity similar to current treatments will not allow development of more targeted 
therapies that may have a differential effect on the same inflammatory pathways in vitro. 
 
MTT assays estimate cell toxicity by testing cell function. Limitations of this in therapeutic drug 
screening can only be understood once human drug toxicity is understood. Toxicity of drugs in 
humans (or animals) requires modulation of complex multi-factorial physiological systems that lead 
to tissue damage124. In vitro studies of toxicity have failed to simulate these complex environments 
and therefore can only be used to quantify well-understood cellular and molecular routes of 
damage. Their use is therefore limited to generic cellular or sub-cellular toxicity leaving in vivo 
toxicity estimations to the in vivo models alone124. 
 
This thesis outlines screening and purification of a selection of Australian botanical extracts based 
on their bioactivity to inhibit IL-1β, TNF-α and NF-κB translocation. Near-pure compounds that 
share these properties have been discovered and their classification, production and testing in vivo 
will be required in the future if they are to become treatments for CRS or other similar chronic 
inflammatory conditions. 
 
5.1 Summary 
Chronic rhinosinusitis is a disease of significant health burden with current therapeutic options 
leaving a select group of recalcitrant patients with ongoing symptoms. This disease is 
characterised by a pattern of inflammation of which cytokines IL-1β and TNF-α as well as signal 
transduction through translocation of NF-κB play a central role. 
 
As biological extracts have proven to be active against these inflammatory pathways this research 
investigated four such extracts and through quantification of the modulation of these pathways; 
guided fractionation of these to near-pure compounds retaining these anti-inflammatory properties. 
To achieve this a high-throughput model of screening using macrophage-like cells artificially 
stimulated by LPS was used along with ELISA and quantitative florescent microscopy to quantify 
cytokine release and NF-κB translocation respectively. 
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As three of these near-pure compounds were not toxic to the screening assay they may be 
candidates for further studies including NMR characterisation and in vivo therapeutic studies 
before their use as potential anti-inflammatory agents may be known. 
 
5.2 Future directions 
The final generation of fractions may be a mixture of a small number of compounds and these 
compounds may need to be further isolated and identified if a pure and novel drug is to be 
discovered as a consequence of this study. To carry out this task spectral analysis of the near-pure 
compound is a valuable resource. Nuclear magnetic resonance (NMR) is the study of molecular 
structure through measurements of electromagnetic interactions and generates “peaks” based on 
the different properties of the compounds tested. Comparing these peaks to peaks of known types 
of chemicals leads to characterisation of unknown chemical composition126. Many similar studies 
into biological compounds arising from extracts have used NMR to effectively name their active 
ingredients127,128. 
 
Further in vitro testing of these compounds may serve to whittle down mechanistic pathways for 
their action. Some researchers investigating biological extracts for CRS have focused on different 
signalling pathways such as IL-6 and signal transducer and activator of transcription-3 (STAT3) for 
andrographolide (from Andrographis paniculata) as IL-6 is over expressed in the CRSwNP subtype 
of the disease129. STAT3 studies in this area focus on phosphorylated STAT3 or p-STAT3 using 
semi-quantitative gel electrophoresis130,131 which makes their use in high-throughput sreening less 
appealing. It is possible to perform a similar high-content screening assay using p-STAT3 
translocation rather than NF-κB and in this way these fractions or other extracts may be screened 
for this activity. Subsequently STAT3, like NF-κB is implicated in the proliferation of many 
malignancies132,133 and therefore may be of interest to other areas of research. Other pathways 
such as MEK1/2-ERK1/2134, p38 MAPK/JNK135 have been implicated in CRS as well as 
inflammatory proteins and cytokines such as COX-2136 and others mentioned in chapter 1. These 
inflammatory cytokines could be screened for with ELISA or a similar high-throughput technique. 
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Compounds that show promise in vitro, with low toxicity in vitro, require a more complex study of 
their toxicity potential in human tissue before they may be inserted into a living model.  Animal 
explant models or ex vivo models can be effective in determining toxicity to the cilia and may 
originate form mice137 or pig138 while human explant models using nasal tissue are also 
available139. As human nasal tissue is often removed electively for sinus and nasal procedures 
human explant models are relatively inexpensive and readily available. 
 
Successful identification of a potential therapeutic anti-inflammatory agent for use in CRS would 
necessitate in vivo studies. Typically these may involve larger animal models such as canine140, 
rabbit141, sheep142 or mouse143. Animal studies such as rabbit involve creating an artificial blockage 
in the sinus either surgically or with biological foam along with implanting a sinus pathogen143. 
Histological evaluation of the rabbit model revealed similar aggregation of immune cells when 
compared to human sinusitis indicating that these models would be effective in testing therapeutic 
agents144. A sheep model of CRS has gained popularity in Australia and has been used to study 
etiological factors145 as well as therapeutic options for CRS142 making it a likely choice for further 
therapeutic in vivo research here in Australia. 
 
On a wider scale the future direction of these extracts is not exclusive to the relative anti-
inflammatory activity of the selected third generation fractions. Many areas of research search for 
different properties in these extracts and as such stimulatory extracts from this research may be of 
interest to these researchers. EBC 46 is a novel protein kinase C inhibitor that arose from the 
same database of biological extracts is a known anti-cancer agent and has been shown to 
increase NF-κB translocation and cytokine IL-1β release146. Stimulators of these inflammatory 
pathways may provide the necessary immunomodulation to fight malignancies or other conditions 
and are therefore valuable for future research in their own right. 
 
Commercial production of novel therapeutic agents derived from biological sources ban be 
achieved in one of two ways. Firstly synthesis of biological compounds can be achieved in some 
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cases biochemically147 and this may lead to wide scale commercial synthesis. Some drugs derived 
from biological sources however are produced by extraction from a naturally grown source such as 
morphine and its derivatives which have been synthesised though not in a commercially viable 
method148. The considerations of which method of commercial production must also take into 
account the environmental impact of parent plant growth, harvest and fractionation verses 
chemical synthesis. 
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7.0 Appendices 
 
 
7.1 Appendix 1 - Alphabetical List of Materials* 
Name Source Catalogue number 
AlphaScreen ELISA Assay Perkin Elmer  
Bovine serum albumin Research Organics, Cleveland, 
Ohio, USA 
 
DAPI Sigma-Aldrich 32670 
FBS Invitrogen F9423 
Formaldehyde Sigma-Aldrich 252549 
Goat anti-rabbit secondary 
antibody 
Abcam, Cambridge, UK  
Goat serum Sigma-Aldrich G9023 
LPS Enzo Life Sciences, New York, 
USA 
 
MetaXpress™ software Molecular Devices 
Corporation, Downington, PA, 
USA 
 
Multilabal plate reader 
(Enspire-Alpha 2390) 
Perkin Elmer  
PBS Amersco, Solon, USA  
Penicillin-streptomycin Invitrogen 15070-063 
Perkin Elmer OptiPlate-384 Perkin Elmer 600-7290 
PMA Axxora ALX-445-004 
Rabbit anti-CD11b primary 
antibody 
Abcam, Cambridge, UK  
Thiazolyl Blue Tetrazolium Sigma-Aldrich M5655 
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Bromide Cell Proliferation 
Assay (MTT) 
THP-1 cells Associate Professor Marie-
Odile Parat, School of 
Pharmacy, University of 
Queensland, Brisbane, 
Australia 
 
Tissue culture flasks and 
plates 
Sigma-Aldrich  
Triton X-100 Sigma-Aldrich T8787 
*List of materials excludes those involved in fractionation as this was done kindly by the QIMR 
laboratory on behalf of the author. 
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7.2 Appendix 2 – Standard curves 
7.2.1 Human IL-1β AlphaScreen ELISA Standard Curve 
Lyophilised human IL-1β (Sigma-Aldrich) (0.1 µg) was reconstituted in 100 µL of sterile water and 
subsequently diluted in media containing RPMI 1640 with FBS 1% to allow a range of 
concentrations of human IL-1β. The dilutions are prepared according to the table below. 
 
Human IL-1β AlphaSreen ELISA Standard Curve 
Tube Volume of human IL-1β 
(µL) 
Volume of diluent (µL) Human IL-1β in standard 
curve (g/mL in 5 µL) 
A 5 µL of reconstituted 
human IL-1β 
45 1 x 10-8 
B 30 µL of tube A 70 3 x 10-9 
C 30 µL of tube B 60 1 x 10-9 
D 30 µL of tube C 70 3 x 10-10 
E 30 µL of tube D 60 1 x 10-10 
F 30 µL of tube E 70 3 x 10-11 
G 30 µL of tube F 60 1 x 10-11 
H 30 µL of tube G 70 3 x 10-12 
I 30 µL of tube H 60 1 x 10-12 
J 30 µL of tube I 70 3 x 10-13 
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7.2.2 Human TNF-α AlphaScreen ELISA Standard Curve  
Lyophilised human TNF-α (Sigma-Aldrich) (0.1 µg) was reconstituted in 100 µL of sterile water and 
subsequently diluted in media containing RPMI 1640 with FBS 1% to allow a range of 
concentrations of human TNF-α. The dilutions are prepared according to the table below. 
 
Human TNF-α AlphaScreen ELISA Standard Curve 
Tube Volume of human TNF-α (µL) Volume of diluent (µL) Human TNF-α in standard 
curve (g/mL in 5 µL) 
A 5 µL of reconstituted human 
IL-1β 
45 1 x 10-7 
B 30 µL of tube A 70 3 x 10-8 
C 30 µL of tube B 60 1 x 10-8 
D 30 µL of tube C 70 3 x 10-9 
E 30 µL of tube D 60 1 x 10-9 
F 30 µL of tube E 70 3 x 10-10 
G 30 µL of tube F 60 1 x 10-10 
H 30 µL of tube G 70 3 x 10-11 
I 30 µL of tube H 60 1 x 10-11 
J 30 µL of tube I 70 3 x 10-12 
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7.4 Appendix 4 - Buffer composition 
7.4.1 AlphaScreen ELISA immunoassay buffer 
250 mM HEPES, pH 7.4 
1% Casein 
10 mg/mL Dextran-500 
5% Triton X-100 
0.5% Proclin-300 
 
7.4.2 Phosphate-buffered saline (PBS) 
137mM NaCl 
2.7mM KCl 
10 mM NaH2PO4 
1.8 mM KH2PO4 
 
7.4.3 Blocking buffer 
10% 10 x PBS v/v 
5% goat serum v/v 
0.3% Triton X-100 v/v 
 
7.4.4 Antibody dilution buffer 
10% 10 x PBS v/v 
0.3% Triton X-100 v/v 
1% bovine serum albumin w/v 
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Appendix 7.5 – HPLC profile for reverse phase elution on methanol-water 
The HPLC fractionation was performed by QIMR using reverse-phase fractionation over methanol-
water. The relative concentrations of the elutant remains intellectual property of QIMR though a 
profile of the fractionation is seen below. 
 
